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ABSTRACT OF DISSERTATION

MECHANISM OF ANTIBIOTIC PERMEABILITY THROUGH THE GRAMNEGATIVE BACTERIAL ENVELOPE
The outer membrane of Gram-negative bacteria (GN) makes them distinct among
superbugs that are associated with the development of antibiotic resistance. The outer
membrane, and inner membrane, separated by the periplasm, form a double-membrane
barrier to the entry of antibiotics into the cell. Several studies have been conducted to
examine the role of outer membrane modifications such as porins, lipopolysaccharides, and
efflux pumps on antibiotic resistance. However, there is a paucity of knowledge on how
antibiotics behave in the periplasm, to gain access into their target region. My thesis
focuses on understanding the mechanism of antibiotic permeability through the cellular
envelope of Gram-negative bacteria.
I studied the distribution of fluoroquinolones in the two aqueous compartments
(periplasm and cytoplasm) of Escherichia coli using fluorescence intensity measurement
and minimum inhibitory concentration (MIC) test. We treated the bacteria cells with each
antibiotic, allowed the antibiotic to accumulate in the cells, fractionated the cells and
quantified the concentration of accumulated antibiotic through the measurement of its
fluorescence intensity. The compound accumulation assay showed that the efflux-deficient
strain (tolC) accumulated more antibiotic than the wild type (WT) strain, for all nine
fluoroquinolones tested. An analysis of the subfractions showed a greater accumulation of
the antibiotic in the periplasm than in the cytoplasm. A positive correlation was observed
between the MIC ratio (WT/tolC) and the cytoplasmic accumulation ratio (tolC/WT).
This is an indication of the importance of measuring accumulation in the target rather than
the whole cells.
I also studied the impact of osmo-regulated periplasm glucans (OPGs) on antibiotic
susceptibility in GN. We created E. coli and Salmonella Typhimurium strains deficient in
OPG production. We also created an E. coli strain that produced neutral OPGs. The drug
susceptibility test showed that the strains that are either deficient in OPG production or
produce neutral OPGs were less susceptible to some of the positively charged
aminoglycosides compared to the WT strain. A similar response was observed when the
bacteria strains were treated with the fluoroquinolones and tetracyclines. We speculate that
this behavior is due to the net positive charge carried by these antibiotics from complexes
formed with Mg2+. In contrast, the strains grew slower in the presence of negatively
charged cefuroxime and neutral linezolid. The observed MIC changes were not due to a
leaky membrane. The OPG deficient strains produced significantly reduced amount of
OPGs compared to the parent strain. Our study demonstrated that charge plays a significant
role in OPG-mediated susceptibility to antibiotic.

We also probed the role of OPGs on copper homeostasis in GN bacteria. We found
that the disruption of the opgGH operon had an impact on the tolerance of GN bacteria to
copper. Copper quenched the fluorescence of cytosolic GFP faster in the OPG- deficient
strains compared to the WT strain. The GFP-quenching effect of copper ions was
diminished with the increase of ionic strength, indicating that Cu 2+ penetration into the
cytoplasm slowed down under high salt condition.
KEYWORDS: [Gram-negative bacteria, cellular envelope, antibiotic, osmo-regulated
periplasmic glucans, accumulation, charge]
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CHAPTER 1.

INTRODUCTION

Reproduced in parts from Antibiotics, 2021, 10 (6), 701 with permission from publisher,
MDPI 20211.

1.1

Antibiotics: Origin, Development, and Future
Antibiotics are natural extracts or synthetic substances administered to treat

bacterial infections

2-4.

Historically, before the production of antibiotics on a large-scale

by synthetic chemists, people have devised traditional means to treat their bacterial
infections. Ancient Egyptians treated their wounds and burns with filamentous fungi
growth on bread5. The Greeks and Chinese managed their aliments with musty textures6.
Large scale production of antibiotics dates to the early 20th century, when one of the
organo-arsenic derivatives of Atoxyl, arsphenamine, synthesized by Paul Erlich and coworkers, showed activity against Treponema pallidium 7.

This drug marketed as

Salvarsan, gained so much popularity for over 30 years until Alexander Fleming
discovered penicillin in 19408. Paul Erlich and co-workers set the precedence for drug
discovery through their large-scale and systematic screening program. This systemic
approach to drug design and production has led to the emergence of several effective
antimicrobials,

including

sulfa

drugs

(Pronstil),

quinolones

(nalidixic

acid),

oxazolidinones (linezolid), and their derivatives 9-11.
The discovery of penicillin in 1929 by Alexander Fleming commenced the era of
antibiotics isolated from microorganisms 12. He observed growth inhibition zones on his
agar-dishes that bore Penicillium strains and attributed the inhibitory activity of the
microbe to its secretion. Other scientists before 1929, have observed antagonist behaviors
between micro-organisms13-18. However, his tenacity in the pursuit of his serendipitous
discovery, made him unique. This led to the establishment of techniques to isolate and
purify antibiotics from other microbes, including Pyocyanase from Pseudomonas
aeruginosa, antimicrobial peptides from plant and animal sources19,

20.

All thanks to

Alexander Fleming, the microbial zone of inhibition test has remained a valuable tool in
bacteriology for both instructional and research laboratories.
1

The triad of Salvarsan, Prontosil and penicillin formed the scaffold upon which
scientists in the Golden era synthesized tons of novel antimicrobials under 23 different
classes. The Golden era spanned between 1940s and 1970s, which has been accompanied
by a hush in the discovery of new antibiotics2. Clinically relevant classes of antimicrobials
discovered during and shortly after the Golden era, included nitrofurans (1963),
quinolones (1960), sulphonamides (1961), oxazolidinones (1987), daptomycin (1986).
Post-Golden era, with the emergence of drug resistance, infectious diseases have been
combated with modified pre-existing antibiotics or the use of combination therapy21-23 .

1.2

Classes of Antibiotics and their Mechanism of Action
Antibiotics can be classified into two broad classes: bactericidal (bacterial killing)

and bacteriostatic (bacterial growth inhibition)24. These classes can be sub-categorized
based on their site of action in the cell, which is shown in table 1.1.

Table 1.1 Antibiotics and their mode of action
Antibiotic class
Beta lactams

Some examples
Cephalosporins
Penicillin

Cellular target
Cell wall mainly
peptidoglycan biosynthesis25

Lipopeptides

Daptomycin

Cell membrane26

Cationic peptides

Colistin

Cell membrane27

Pyrimidines

Trimethoprim

C1 metabolism28

Sulfonamides

Sulfamethoxazole

C1 metabolism29

Quinolones

Ciprofloxacin, Norfloxacin,
Enrofloxacin

DNA gyrase30

Rifamycin

Rifampin

Transcription31

Aminoglycosides

Amikacin
Streptomycin
Gentamicin

Translation32

2

Table 1.1 continued

1.3

Tetracyclines

Tetracycline
Chlortetracycline
Minocycline

Translation33

Lincosamides

Clindamycin

Translation34

Oxazolidinones

Linezolid

Translation35

Phenicol

Chloramphenicol

Translation35

Macrolides

Erythromycin
Azithromycin

Translation36, 37

Antimicrobial Multidrug Resistance (AMR) in Gram-negative Bacteria
In all living organisms, the membrane envelope defines the boundary of the cells

and serves to protect the cellular content from the external environment. The composition
of the cell envelope is different between Gram-positive (GP) and GN bacteria. In GP
bacteria, there is a single cytoplasmic membrane and a distinct cell wall made of a thick
peptidoglycan layer38. In contrast, GN bacteria contain a cytoplasmic or inner membrane
(IM), a thin peptidoglycan layer, and an outer membrane (OM) (Figure 1.1). The OM
constitutes an extra protection barrier, contributing to the high level of intrinsic multi-drug
resistance in GN bacteria39. The lipid and protein composition of the OM and IM varies40,
41.

The IM is a typical phospholipid bi-layer rich in phosphatidylethanolamine,

phosphatidylglycerol, and cardiolipin42, 43. Conversely, the OM is an atypical phospholipid
bilayer with an external leaflet composed of a lipopolysaccharide (LPS) monolayer and an
internal leaflet of a phospholipid monolayer, similar in lipid composition with the IM44,

3

45.The

OM is rich in β-barrel proteins such as porins, which has been the focus of several

excellent reviews40, 46.

Figure 1.1 Cell envelope of the Gram-negative bacteria is composed of two layers of lipid
bilayer membranes and an aqueous periplasmic space sandwiched in between. The outer
membrane (OM) is an asymmetric bilayer with lipopolysaccharide (LPS) on the outer
leaflet and phospholipids on the inner leaflet. Porins on the OM aid passive diffusion of
nutrients and antibiotics. The inner membrane (IM) is composed of phospholipids and
contains transporters. A thin layer of peptidoglycan (PG) cell wall exists in the periplasm,
which is anchored to the outer membrane by Bruan’s lipoprotein (Lpp). The periplasm is
also rich in macromolecules including proteins and glycans. OPGs are special glucans with
a glucose backbone and modifications such as phosphoethanolamine, phosphoglycerol,
and succinyl residues. OPGs contribute to the net negative potential across the OM. The
selective permeability of the outer membrane leads to the development of a membrane
potential. The figure was created using BioRender.com.
The porins and efflux pump systems play opposite roles in the permeation of
substances, including antibiotics, bile acids, ions, and dyes across the cell envelope of GN

4

bacteria47-49. The porins allow the permeation of small hydrophilic substances across the
OM since these beta-barrel structures possess water filled pore channels50, 51. Some of these
porins including LamB, YddB, EadL, and PgaA promote the passive diffusion of specific
antibiotics while others such as OmpA, OmpC, and OmpF are non-specific in their
selection of antibiotics 40, 51, 52. In contrast, the efflux pump systems promote the expulsion
of antibiotics from the cell into the extracellular space. The efflux pump systems are
classified into six families including the resistance nodulation cell division (RND) family,
the ATP binding cassette (ABC) family, the major facilitator superfamily (MFS), the small
multidrug resistance (SMR) family, the multidrug and toxic compound extrusion (MATE)
family, and the related proteobacterial antimicrobial compound efflux (PACE)

53, 54.

The

RND, some ABC and MFS efflux pump systems possess three components that transverse
the full length of the cell envelope. The three components include the IM export protein
adapted by a periplasmic protein to an OM channel (figure 1.2). The PACE and MATE
efflux pumps possess a single component associated with the IM and they promote efflux
of antibiotics from the cytoplasm into the periplasm.
Depending on features such as size, net charge and hydrophobicity, substances can
permeate the OM through porins or by disruption of the LPS barrier. Most substances in
the extracellular space must contend with the LPS barrier when they cross the OM into the
periplasm. The LPS are complex polysaccharides with the lipid A modification forming
the primary component of the outer leaflet of the OM55 . Adjacent LPS molecules are linked
by divalent ions to form a structural barrier against in-coming antibiotics in the surrounding
medium56. Disruption of these Mg2+ ion bridges create hydrophobic patches on the OM,
which allows hydrophobic substances to permeate the OM48. In contrast, the OM is a
hydrophobic barrier preventing the permeation of hydrophilic substances. The hydrophiles
permeate the OM through an alternative route known as porins. Upon arrival in the
periplasm, the substances can interact with components of the periplasm such as enzymes,
binding proteins, peptidoglycan layer and osmo-regulated periplasmic glucans (OPGs)5760.
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1.4

Donnan Potential (DP) influences antibiotic transport across the Outer
membrane
DP has been recognized as an important factor in antibiotics permeability through

the OM in GN bacteria. The term “Donnan potential” was first described by Teorell et al.
and measurement of this potential across the OM of GN bacteria, E. coli and Salmonella
Typhimurium, was first reported by Stock et al. 61, 62. The discovery of OPGs by Schulman
and co-workers led to the measurement of DP across the OM of GN bacteria63-66. The field
of study involving DP in bacterial cells has evolved progressively in the last 50 years.
Studies in the first 25 years focused on understanding the adaptation to osmolarity and its
influence on the DP across the OM and membrane permeability61, 67-71. In addition, DP has
been identified as a surface potential in GP bacteria involved in cell mobility and adaptation
to pH changes during this period72-78 . In the recent 25 years, research focus shifted to the
involvement of DP in the cell surface behavior in response to different environmental
stimuli including charge, ionic strength, and pH79-85. In addition, the role of DP on
compound accumulation in bacterial cells attracted research interest, in a bid to solve the
fast-evolving problem of antibiotic resistance in bacteria86-89.
DP arises from an imbalance in charges that result from small permeable ions
crossing the OM freely in the presence of large impermeable charged molecules trapped in
the periplasm. No active pumps are needed to maintain this potential, which is negative on
the periplasmic side and normally contributes approximately 40 to 80 mV to the overall MP
across the OM61, 68, 84, 90, 91. This net negative potential acts as a driving force to pull in
positively charged antibiotics across the OM. This voltage is less than the estimated 150–
200 mV MP across the IM of E. coli 81.
1.4.1

OPGs contribute to the generation of DP

OPGs in most GN bacteria are acyclic and contain 6–12 glucose units linked by the
β-1,2 glycosidic bonds in the parent chain and β-1,6 glycosidic bonds in the branches92, 93 .
Most OPGs are decorated with charged functional groups such as Sn-phosphoglycerol,
phosphoethanolamine, and O-succinate63, 94 , thus on average OPGs carry a net negative
charge of −5 per molecule63, 95. OPGs are trapped in the periplasmic space after biosynthesis,
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due to their hydrophilicity and large molecular weight of approximately 2.5 kDa61, 96. The
charged OPGs contribute to an excess of negative charges in the periplasm of most GN
bacterial cells61,

96.

In this negatively charged form, OPGs can act as electrostatic

counterions and concentrate cations in the periplasm81. For example, in a recent molecular
simulation study on the behavior of antibiotic polymyxin B1 in the periplasm, OPGs have
been found to be a major interactor that forms prevalent interaction with the drug97 .
OPGs are maximally synthesized when bacterial cells are grown in hypoosmotic
media and minimally synthesized when grown in hyperosmotic media68, 96, 98-101. Lacroix
and co-workers reported that E. coli cells grown in a medium of low osmolarity (100 mOsm)
synthesized a high level of OPGs, making up approximately 5% of the total dry weight of
the E. coli cells101 . This amount dropped 10-fold to approximately 0.5% when the cells
were grown in a media with a high osmolarity of 600 mOsm. A study by Martinez et al.
showed that DP decreased from −47.9 to −3.5 mV in E. coli when the K+ concentration in
the external media increased from 10 to 500 mM 82. An increase of the external osmolarity
could play two roles leading to the reduction of DP: the direct reduction due to high ionic
strength and the indirect effect through reducing OPG production.
1.4.2

Synergy between Porins and DP in Cation Selection and Cellular
accumulation

Porins are important components of the OM in GN bacteria. The most abundant
porins in E. coli are OmpA, OmpF, and OmpC. While OmpF and OmpC are non-specific
porins that are associated with passive diffusion of small molecules, OmpA is involved in
the maintenance of membrane integrity39, 40. Since DP and antibiotic permeability are the
focus of this review, OmpC and OmpF are of special interest, which are both cationselective and permeable to different substrates including many antibiotics.
OmpC and OmpF are structurally very similar and yet different in their conductivity.
OmpC is more cation selective than OmpF because it has a more negative interior, while
OmpF is more permeable than OmpC under normal physiological conditions due to its
larger pore size102. Kojima and Nikaido showed in their study that mutations of specific
residues lining the translocation pathway of OmpC or an increase of the ionic strength of
the external environment can make OmpC as permeable as OmpF 103. Their result revealed
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that an increase of NaCl concentration from 0 to 0.3 M resulted in an elevated permeability
of OmpC to ampicillin, benzylpenicillin, and lactose to levels like OmpF. In contrast, nonionic osmolytes such as sucrose, sorbitol or polyethylene glycol had no impact on the
permeability of either OmpC or OmpF.
Other than directly changing porin conductivity, the osmolarity of the external
media also influences the expression levels of porins. OmpF is induced in bacteria under
conditions of low osmolarity47, 67, 104. In contrast, OmpC, a so-called osmoporin, is induced
under conditions of high osmolarity105 . This opposing effect has been proposed to be an
adaptive strategy to maximize nutrients uptake under different conditions104. Intriguingly,
low osmolarity also induces increased biosynthesis of OPGs as discussed above. This
suggests that a synergy may exist between the functions of OPGs and the porins.

1.5

Impact of DP on Susceptibility to Antibiotics in Bacterial Infection
In the clinical setting, GN bacteria play key roles in the emergence of bacterial

infections as shown in Table 1.2. Among these bacteria, E. coli and P. aeruginosa are the
top causative agents for these infections. Additionally, two thirds of the six bacteria
notorious for antibiotic resistance, termed ESKAPE, are GN106, 107.

Table 1.2 Major Gram-negative bacteria pathogens as causative agents of bacterial
infections.
Diseases/Conditions
Brucellosis
Cholera

Associated Gram-negative Bacteria

108, 109

Brucella spp.

110, 111

Vibrio cholerae
E. coli, Salmonella spp., Shigella spp.,

Gastroenteritis112-114
Gonorrhea

Campylobacter jejuni

115, 116

Neisseria gonorrhoeae

Legionnaires’ Disease117, 118
Pertussis
Plague

Legionella pneumophila

119, 120

Bordetella pertussis

121

Yersinia pestis

Table 1.2 continued
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E. coli, Klebsiella pneumonia, Acinetobacter

Respiratory tract infection, Pneumonia122-124

baumanii, Pseudomonas aeruginosa

Shigellosis125-127

Shigella spp.
E. coli, Klebsiella pneumonia, Acinetobacter

Surgical wound infection128-130

baumanii, Pseudomonas aeruginosa

Tularemia131

Francisella tularensis
132, 133

Typhoid fever

Urinary tract and urinary-catheter infections

Salmonella typhimurium
134-138

E. coli, Klebsiella pneumonia

The presence of the OM in the GN bacteria is a bi-factor contributor to antibiotic
resistance based on the impairment of compound penetration and enhancement of
compound loss through efflux pumps. In addition, the periplasmic space between the OM
and IM houses potential binders and metabolic inactivators, that could alter antibiotic
activity. These factors are shown in figure 1.2

Figure 1.2 Mechanisms of antimicrobial multidrug resistance in Gram-negative bacteria.
(1) Modified targets lose ability to bind the antibiotic. (2) Drug is degraded by intracellular
enzymes. (3) Antibiotics are expelled by the active efflux pumps. (4) Antibiotics lose
ability to penetrate an impaired OM.
These factors constitute a barrier to the design of new antimicrobials to curb
antibiotic resistance in GN bacteria. Most compounds effective against GN bacteria are
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potent against GP bacteria but the reverse is not the case139. A good drug with activity
against GN bacteria should combine the ability to permeate the OM and IM as well as evade
the efflux pumps107. Frustratingly, the entry rule is not that simple for GN bacteria when
compared to GP bacteria because physicochemical properties that promote penetration
across the OM of GN bacteria oppose diffusion across their IM107, 140. For instance, small
hydrophilic compounds are good OM penetrators via porins and poor substrates for efflux
pumps but slow penetrators across the IM. On the contrary, relatively large lipophilic
compounds are good IM penetrators but poor OM penetrators and good substrates to efflux
pump systems. A balance would be amphiphilic compounds such as fluoroquinolones and
tetracyclines with multiple protonation sites that can cross the OM as charged complexes
and diffuse through the IM as neutral species141. Then, again, the presence of potential
binders in the periplasm stalls their antibacterial activity especially for those with targets in
the cytoplasm. Silver published an excellent review on GN entry for antibiotics142.
The impact of DP on bacterial infections is indirect and occurs through two means,
alteration of bacterial virulence and adaptation to changes in osmolarity.
1.5.1

Alteration of Bacterial Virulence

Disruption of OPGs biosynthesis have been shown to impact bacterial virulence,
suggesting a role of DP in the adaptation of bacteria in the host system99, 143-147 . MahajanMiklos et al. reported a reduction in virulence when mice models were infected with
Pseudomonas aeruginosa strain 36A4, which possessed mutation on the opgH-like locus146
. Bhagwat et al. reported a decrease in virulence after 15 days when mice models were orally
infected with Salmonella Typhimurium opgGH mutant strains as compared to the wild type
strain and the opgGH mutant complemented with plasmid pBK1699. Bowe et al. constructed
a bank of 330 independent mutants of Salmonella Typhimurium, which were screened for
loss of virulence in a mice model148 . The infected mice were monitored for 28 days. Their
result showed that CL288, a mutant strain with an insertion in a gene sequence homologous
to opgB, had attenuated virulence in the mice model149. OpgB contributes to the anionic
charge of OPGs which indicates that DP may contribute to the virulence of the bacteria.
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1.5.2

Impact on Susceptibility of Bacteria to Antibiotics

OPGs are key factors in the adaptation of GN bacteria to osmotic changes in the
external environment99,

101.

Under conditions of high osmolarity, OPG production is

minimized. The decreased OPG level is associated with a reduction in DP as well as a loss
of the ability to concentrate positively charged antibiotics in the periplasm. Therefore, the
bacteria become less susceptible to these antibiotics99 . Medeiros et al. reported the effect of
varying ionic strength of different media on the susceptibility of three GN bacteria to
gentamicin150. Pseudonomas aeruginosa, Serratia marcescens, and E. coli K12 were the
representative strains. For bacteria grown in nutrient broth, the minimum inhibitory
concentration (MIC) of gentamicin increased 130-fold (P. aeruginosa), 8-fold (S.
marcescens), and 36-fold (E. coli), when the concentration of MgCl2 increased from 0 mM
to 29 mM. Alteration of the ionic strength which involved NaCl gave a similar result as with
MgCl2. The MIC of gentamicin against P. aeruginosa increased 67 folds when the
concentration of NaCl increased from 2.7 mM to 174 mM.
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CHAPTER 2. DISTRIBUTION OF FLUOROQUINOLONES IN THE TWO
AQUEOUS COMPARTMENTS OF ESCHERICHIA COLI
Reproduced in parts from Biochemistry and Biophysics reports, 2020, 24, 100849 with
permission from publisher, Elsevier 202086.

2.1

Introduction
Antibiotic resistance in GN bacteria is a global challenge151. In the United States, the

number of cases with antibiotic resistance is on the rise with an annual record of 35
thousand deaths152. The number of deaths in North America is projected to hit about
320,000 by 2050152. After the Golden era, there has been a big gap in the pace of drug
discovery and the emergence of drug resistance in GN bacteria153. To improve the efficacy
of an antimicrobial against GN bacteria, it must be able to circumvent the mechanisms of
drug resistance such as the OM barrier, degradation by intracellular enzymes, and
modification of its target154. The OM barrier consists of porins, lipopolysaccharides, and
efflux pump systems. The OM barrier in GN bacteria is the primary factor that narrows the
spectrum of activity of drugs effective against GP bacteria1, 155 .
Intracellular accumulation of antibiotics should be sufficient to result in either
bactericidal or bacteriostatic effect. Previous studies have been done to assess
fluoroquinolone accumulation in the bacterial cell and correlation were made with
parameters such as minimum inhibitory concentration (MIC) of the drug, target inhibitory
activity, and hydrophobicity156-160. The studies revealed that there was no correlation
between the MIC of the fluoroquinolones and its cellular accumulation in the bacterial
strains tested including E. coli, P. aeruginosa, S. aureus, Mycobacterium tuberculosis, and
Streptococcus pneumoniae87, 156-158, 160, 161. In most of these studies, a correlation was found
between the effective dose and the MIC160. The hydrophobicity of the fluoroquinolones
correlated either positively or negatively with its accumulation in different bacterial
species. A positive correlation was observed in S. aureus and Mycobacterium tuberculosis
while a negative correlation was observed in E. coli, Streptococcus pneumonia and P.
aeruginosa156, 158, 160. Lyer et al. quantified the accumulation of fluoroquinolones in E. coli
and found that there was no correlation between the whole cell accumulation of the drug
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and its bacteriostatic effect159 This points to the relevance of the accumulation in the site
of action of the drug.
Fluoroquinolones are derivatives of the quinolone family of antibiotics. There are
four generations of quinolones. Nalidixic acid is the parent compound of the first
generation of quinolones162-164.

Figure 2.1 Generations of quinolones that have been licensed for clinical use.
Fluoroquinolones are antibiotics with several modifications on the core structure
that promotes a broad spectrum of activity against both GP and GN bacteria165. They are
clinically relevant antibiotics. Fluoroquinolones inhibit the activity of DNA gyrase in GN
bacteria and DNA topoisomerase IV in GP bacteria 166-168. Intracellularly, fluoroquinolones
form a ternary complex with DNA and DNA gyrase. In this conformation,
fluoroquinolones prevent DNA gyrase from catalyzing the formation of negative supercoils
by stopping the re-ligation step. The downstream effect of this inhibition is the alteration
of DNA replication, transcription, repair, recombination, and transposition169-171.
Fluoroquinolones are a top pick for most drug accumulation studies because of their
intrinsic fluorescence87,

172-175.

In this study, we assessed the accumulation of nine

fluoroquinolones in the periplasm and cytoplasm of an E. coli efflux deficient strain
(tolC) and the parent strain. We also performed a drug susceptibility test by determining
the MIC of each fluoroquinolone in the each tolC strain as compared to the parent strain.
We used these two strains as a pair since the only difference between them is the cellular
accumulation of the compounds, thus the MIC difference will reflect the impact of
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differences in cellular accumulation. A plot was done to ascertain the correlation between
the subcellular compound accumulation and the drug activity. We hypothesize that a
combination of the ability of the antibiotics to accumulate in the target region and inhibit
the target determines its antibacterial activity.

2.2

Materials and Methods
2.2.1

Bacterial strains, plasmids, and growth condition

E. coli BW25113 (wild type) and the isogenic efflux deficient strain
BW25113tolC were obtained from the Yale Coli Genetic Stock Center and used for the
drug accumulation studies. All fluoroquinolones were purchased from Sigma-Aldrich and
silicon oil was purchased from Fischer-scientific.
2.2.2

Buffer composition

a) NaPi-Mg buffer (50 mM sodium phosphate, [pH 7.0], 0.25 % Magnesium chloride)
b) Periplasmic preparation buffer (200 mM Tris-Cl, 20% sucrose, 1 mM EDTA, 1 mg/ml
lysozyme).
c) Glycine-HCl buffer (0.1 M glycine, [pH 3.0], pH adjusted with 5 M HCl).
d) Tris buffer (200 mM Tris-Cl, [pH 8.0]).
2.2.3

Drug accumulation assay

E. coli BW25113 and BW25113 tolC were used in the determination of drug
accumulation. Bacteria cells were cultured in lysogenic broth (LB) to mid-log phase and
harvested at 3000 g for 15 min at room temperature. If not stated otherwise, all subsequent
operations were performed at room temperature. The cell pellets from the spun samples
were re-suspended in a NaPi-Mg buffer to a final concentration of 6.4 at an optical density
of 600 nm (OD 600). The bacterial density was approximately 6.4 x 109 colony forming units
(CFU) per ml. Thereafter, the bacteria suspension was treated with the fluoroquinolone to
a final drug concentration of 2.0 g/ml. The mixture was incubated for 15 min with
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constant shaking at 250 rpm, post-incubation period, 700 l of the drug-treated bacterial
cells was carefully layered on 700 l of silicon oil in a microcentrifuge tube. The sample
was spun at 13000 g for 1 min. The supernatant was discarded, and the inner wall of the
tube was carefully cleaned with a Kim-wipe rod. For the ‘whole-cell’ samples, 1.0 ml of
glycine-HCl buffer was added directly to lyse the cells as described by Piddock et.al 157.
The cell pellet was resuspended in the same buffer and incubated overnight. The next
morning, the sample was centrifuged at 15,000 g for 15 min to remove the cell debris and
membrane. The supernatants were carefully separated and diluted 1:1 with glycine -HCl
buffer before the measure of fluorescence emission spectra.
The subfractions (periplasm and cytoplasm), were obtained as described in (2.2.4)
and 1.0 ml of glycine-HCl buffer was added to each sample, followed by mixing and
overnight incubation. The next morning, the samples were briefly vortexed and then spun
at 15,000 g for 15 min. The supernatant was carefully separated and diluted 1:1 with
glycine-HCl buffer and measurement was done as described for whole cells. The
concentration of the fluoroquinolones that accumulated in the cells was extrapolated from
standard calibration curves based on the maximum intensity at the corresponding excitation
and emission wavelengths (table 2.1).
Table 2.1 Maximum excitation and emission wavelengths used.
Fluoroquinolones

Excitation wavelength

Emission wavelength

(nm)

(nm)

Ciprofloxacin

280

447

Norfloxacin

278

444

Enrofloxacin

278

445

Levofloxacin

293

502

Lomefloxacin

286

450

Ofloxacin

293

501

Fleroxacin

286

453

Marbofloxacin

298

510

Moxifloxacin

296

509
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Figure 2.2 is a flow chart of the procedure. All data presented are done in triplicate
and reported as mean  standard deviation.

Figure 2.2 Experimental flow chart showing the procedure for sample processing.
The effect of wash was evaluated by incubating cells with antibiotics and
centrifuging through silicon oil as described in figure 2.3. The cell pellet was quickly
resuspended in 300 μl of 70 mM Tris buffer (pH 8.0) and spun again at 13,000 g for 1 min.
The supernatant was obtained as the “wash solution”. To the supernatant, 1.0 ml of
Glycine-HCl buffer was added and the concentration of fluoroquinolone in the wash
solution was determined as described for other samples.
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2.2.4

Subcellular fractionation

An osmotic shock method was adopted to extract the periplasm and modification
was made to minimize the incubation time176. The cell pellet from the spun whole-cell
samples was re-suspended in 100 μL of periplasm preparation buffer and incubated for 5
min. Thereafter, 200 μL of ice-cold deionized water was added and the sample was mixed
by mild tapping. The mixture was incubated on ice for 2 min and then spun at 13,000 g for
1 min. The supernatant was separated, which contains the periplasmic component. The
pellet contains the cytoplasm and the cell membrane.
2.2.5

Preparation of the calibration curves

The cell culture was prepared as described for drug accumulation assay except that
NaPi-Mg buffer was used in place of the fluoroquinolone. Cells were aliquoted and pelleted
through silicon oil and the whole cell, periplasm, and cytoplasm extracts were obtained
separately as described in (2.2.4). These solutions served as the background to obtain the
respective calibration curves. Standard solutions of each fluoroquinolone were prepared by
spiking the extracts with a known concentration of each compound. All samples were
vortexed and spun at 15,000 g for 15 min. The supernatant was separated, diluted 1:1 with
glycine-HCl buffer and fluorescence measurements were taken.
The emission spectra of the samples were obtained to determine the maximum
intensity. The calibration graph was plotted with the emission maximum intensity on Yaxis and the concentration of antibiotic on X-axis. All samples were done in triplicate and
plotted as an average with error bars representing the standard deviation.
2.2.6

Quantification of accumulated drug

The measured fluorescence intensity for each sample was converted into
concentration as extrapolated from the corresponding calibration curve. The amount (M)
of the compound is a product of the sample concentration and sample volume, which
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represented whole-cell pellet (Mwc), periplasm (Mpm) or cytoplasm (Mcm) from 0.7 ml of
OD600 = 6.4 bacteria, or 4.5 x 109 cells. The volumes of the whole cell, cytoplasm and
periplasm are 1.0, 1.0, and 1.3 ml respectively.

To calculate the total concentration of drug per cell (Cwc), the mass of the drug in
the whole cell was divided by the actual volume of the cell pellet (16.1 μl):
𝐶𝑤𝑐 =

𝑀𝑤𝑐
16.1

The concentration of the drug in the periplasm (Cp) was determined on the
assumption that the volume of the periplasm is approximately 10% of the total cell volume:
𝐶𝑝𝑚 =

𝑀𝑝𝑚
1.6

Also, the total volume of the cytoplasm was approximately 13.8 μL thus the
concentration in the spheroplast Ccm:
𝐶𝑐𝑚 =

2.2.7

𝑀𝑐𝑚
13.8

Volume of cellular compartments

Based on several studies, a range of 7 to 40% has been reported for the volume of
the periplasm of Gram-negative bacteria

61, 87, 177, 178. 179-183In

an early study by Stock et

al., the periplasmic space of E. coli and S. Typhimurium was reported to be within the
range of 20 to 40% of the total cell volume 61. However, recent studies based on electron
microscopy reported a range of 10 nm to 33 nm as the space between the OM and IM of
Gram-negative bacteria177, 184. A more recent study by Pillzota et al., based on fluorescence
imaging of E. coli cells expressing fluorescent proteins, reported the periplasmic space to
be about 16% of the total cell volume185. Prochnow et al. calculated the volume of the
periplasm to be 7% based on cellular dimensions obtained from different published sources
87.

Based on these findings, in our study we assumed the periplasmic volume to be 10% of

the total cell volume.
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The total volume of E. coli in 1 ml of OD600 =1.0 culture has been reported to be
approximately 3.6 μl186. This value was adopted as the cellular volume for the calculation
of drug concentration in ‘whole-cell’ samples. The cell density in the drug treatment
mixture is OD600 = 6.4. Each pellet contained cells from 700 μL of OD600 = 6.4 culture,
which yielded a total cell volume of 3.6 x 6.4 x 0.7 = 16.1 μl. If 10% of the total volume is
the periplasm, then the volume of the periplasm would be 1.6 μl. Cell membranes have
been estimated to account for 4% of the overall volume, and thus the cytoplasm was 13.8
μl87.

2.3

Results
2.3.1

Drug concentration used during incubation of bacteria

In this study, E. coli cells were incubated with 2 μg/ml of the fluoroquinolone.
Previous studies used between 0.1- 20 ml of the compound during accumulation87, 157,
158.The

external concentration of the antibiotics was kept low to prevent potential

bactericidal effects on the cells, which could alter the results obtained from the
accumulation study. We have previously confirmed that E. coli cells are viable at this drug
concentration.
2.3.2

Reduction of artifacts associated with inefficient removal of residual free
drug

To minimize residual free drug non-specifically associated with the bacteria, we
adopted a procedure that involved passing the cells through a silicon oil layer in a
microcentrifuge tube159, 187.The density of the silicon oil is higher than water but lower than
bacterial cells. After centrifugation, the silicon oil formed a layer between the cell pellets
and the supernatant, which contains extra free drugs (figure 2.3).
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Figure 2.3 Separation process to minimize residual free drug non-specifically associated
with the bacteria.
2.3.3

Subcellular fractionation

The soluble component of E. coli cells was separated into two subfractions,
periplasm and cytoplasm. The periplasmic fraction was carefully separated into a new
microcentrifuge tube. The remaining fraction, being the cytoplasm, was subjected to
overnight lysis. The membrane component was embedded in the cytoplasmic fraction. We
had fewer concerns about the membrane component since previous studies have shown
that the amount of antibiotic- associated with the membrane fraction is insignificant.87
Also, an arduous process is required to separate the membrane from the cytoplasm which
involves 2 min of sonication and an hour of ultracentrifugation 87. Equilibration of the
antibiotic may occur within this period, which would defeat the purpose of fractionation.
2.3.4

Calibration curves

The whole cell, as well as periplasmic and cytoplasmic fractions, was spiked with
standard concentrations of the antibiotic. The spiked samples were resuspended in HClglycine buffer pH 3.0 and kept in the dark to incubate overnight at room temperature. The
fluorescence intensities measured from these samples were used to obtain the calibration
curves. Fluorescence measurements were done using a PerkinElmer precisely LS-55
fluorescence spectrofluorometer and set at a scan rate of 100 nm/s. The calibration curves
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for the three compounds are presented in figure 2.4 below. Ankit Pandeya worked on six
fluoroquinolones, while I worked on enrofloxacin, moxifloxacin, and marbofloxacin
shown in figure 2.6, tables 2.1, and 2.2.

Figure 2.4 Calibration curves for the fluoroquinolones in the whole cell, subcellular
compartments, and the wash solution. These fractions of E. coli BW25113 cells or the
efflux deficient strain were spiked with known concentrations of each fluoroquinolone,
incubated at room temperature overnight and then subjected to spectrofluorometric
measurements.

21

2.3.5

Antibiotic accumulation

As described in the method section, antibiotic accumulation was determined after
incubation of the bacteria cells with the fluoroquinolone. The antibiotic concentration that
accumulated in the whole cell, as well as the subfractions, was extrapolated from the
calibration curves, and presented in Table 2.2. The range of antibiotic concentration that
accumulated in the wild type (WT) strain differed from that of the efflux pump deficient
(∆tolC) strain. For whole cells, the antibiotic concentration ranged from 1.8 to 9.2 μg/ml
in WT strain and 6.0 to 12.6 μg/ml in ∆tolC strain as shown in table 2.2. The subcellular
fractions had a similar trend. For periplasmic fractions, the concentration of antibiotic
ranged from 9.3 to 36.5 μg/ml in WT strain and 42.5 to 69.6 μg/ml in ∆tolC strain. The
cytoplasmic fractions had a range of 0.2 to 6.7 μg/ml in WT strain compared to 1.3 to 8.6
μg/ml in ∆tolC strain. For the nine compounds quantified (with those from Ankit Pandeya
inclusive), enrofloxacin ranked among the top accumulators quantified while moxifloxacin
ranked among the least accumulators. The fluorescence emission spectra for the
enrofloxacin, moxifloxacin and marbofloxacin are presented in figure 2.5 below.
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Figure 2.5 Fluoroquinolone accumulation in the whole-cell and subcellular compartments
of E. coli. The bacteria cells, WT or ∆tolC strain, were subjected to 2 μg/ml of the antibiotic
for 15 min at 28C. Cells were processed and then subjected to spectrofluorometric
measurements.
Table 2.2 Difference (∆) between antibiotic accumulation in subcellular fractions
(periplasm and cytoplasm) and whole cells. Cpm, Ccm and Cwc represent concentrations in
the periplasm, cytoplasm, and whole cell respectively. Similarly, Mpm, Mcm, and Mwc
represent the total amounts in the periplasm, cytoplasm, and whole cell respectively.
Fluoroquinolones

Cpm (μg/ml)

Ccm
(μg/ml)

Cwc

MPm (ng)

MCm (ng)

Mwc (ng)

∆ (ng)

%∆

(μg/ml)

Enrofloxacin ∆C

69.6 ± 0.2

6.0 ± 0.4

12.6 ± 2.0

111.4 ± 0.3

82.8 ± 5.8

203.0± 31.4

8.8

4.3

Enrofloxacin WT

14.2±0.5

1.4±0.4

3.3±0.7

22.7 ± 0.8

19.7 ± 5.2

53.1 ± 11.2

10.7

20.2

Moxifloxacin ∆C

43.0 ± 1.6

3.5 ± 0.3

7.7 ± 0.1

68.8 ± 2.5

48.3 ± 3.5

124.8 ± 0.7

7.7

6.2

Moxifloxacin WT

9.3 ± 0.3

0.8 ± 0.2

1.8 ± 0.1

14.9 ± 0.6

11.0 ± 3.0

28.4 ± 1.1

2.5

8.8

Marbofloxacin ∆C

47.9 ± 3.0

2.4± 0.3

6.2 ± 0.2

76.6 ± 4.9

32.7± 4.7

100.6 ± 3.9

-8.7

8.6

Marbofloxacin WT

24.8 ± 0.7

1.1 ± 0.3

3.0 ± 0.4

39.7 ± 1.1

14.9 ± 3.5

48.6 ± 5.5

-6.0

12.3
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Table 2.2 continued
Ciprofloxacin ∆C

50.9 ± 1.9

8.6 ± 0.1

11.4 ± 1.2

81.4 ± 3.1

118.0± 1.1

183.0 ±18.8

16.5

9

Ciprofloxacin WT

33.9 ± 0.6

5.1 ± 0.4

7.6 ± 0.4

54.2± 1.0

70.2 ± 5.3

123.1± 6.8

1.4

1.1

Norfloxacin ∆C

42.5 ± 2.6

8.1 ± 0.1

11.2 ± 0.1

67.9 ± 4.1

111.4± 0.9

180.8 ± 1.9

-1.4

0.8

Norfloxacin WT

34.0 ± 1.0

6.7 ± 0.1

9.2 ± 0.3

54.4 ± 1.6

93.0 ± 0.5

147.7 ± 4.7

-0.3

0.2

Levofloxacin ∆C

45.1 ± 1.0

1.3 ± 0.2

7.3 ± 0.6

72.2 ± 1.6

17.9 ± 2.2

117.5 ± 2.2

-27.4

23.3

Levofloxacin WT

24.2 ± 1.2

0.6 ± 0.1

3.3 ± 0.1

38.8 ± 1.9

8.7 ± 0.5

52.7 ± 2.4

-5.2

9.9

Lomefloxacin ∆C

56.9 ± 1.5

3.4 ± 0.3

9.3 ± 0.7

91.1 ± 2.4

47.4 ± 5.0

149.3 ± 1.1

-10.7

7.2

Lomefloxacin WT

20.9 ± 1.9

0.7 ± 0.4

2.3 ± 0.4

33.5 ± 3.1

9.5 ± 6.5

37.0 ± 6.4

6.0

16.2

Ofloxacin ∆C

44.0 ± 3.9

1.7 ± 0.2

6.0 ± 0.3

70.4 ± 6.2

23.7 ± 3.1

96.5 ± 4.6

-2.4

2.5

Ofloxacin WT

18.0 ± 1.3

0.2 ± 0.2

2.2 ± 0.2

28.8 ± 2.1

3.0 ± 2.3

35.3 ± 3.2

-3.5

9.9

Flerofloxacin ∆C

62.7 ± 2.2

3.6 ± 0.2

9.1 ± 0.3

100.3 ± 3.5

49.0 ± 3.4

146.4 ± 5.1

3.0

2.1

Flerofloxacin WT

36.5 ± 1.0

1.5 ± 0.1

4.6 ± 0.3

58.4 ± 1.6

20.2 ± 1.7

73.4 ± 4.7

5.2

7.1

We observed heterogeneous accumulation of the antibiotics in the two subcellular
compartments of E. coli. A higher concentration of antibiotic accumulated in the periplasm
compared to the cytoplasm. The higher antibiotic accumulation observed in the periplasm
may have resulted from the DP that exists across the OM of Gram-negative bacteria61, 68,
91, 188.

Also, the efflux pump system can influence a greater loss of antibiotic from the

periplasm than the cytoplasm

189.

Hence, this may account for the distinct margin of

heterogeneous antibiotic distribution observed in the subcellular compartments of the TolC
deficient strain. In a study by Prochnow et al., E. coli cells were treated with 100 ng/ml of
ciprofloxacin and incubated for 10 min. After incubation, antibiotic accumulation in wholecell lysates, as well as in the subfractions, was quantified by LC/MS 87. They observed the
antibiotic concentrated more in the periplasm than in the cytoplasm (221 pg/μl vs 37 pg/μl).
The data points for both calibration curves and accumulation assays are presented
as triplicate and an average ± standard deviation. The standard deviation values are
represented by the error bars in the graphs. In theory, the sum of antibiotic concentrations
obtained from the different subfractions of the bacteria cell should be equal to the
concentration in the intact whole cell. Hence, we used a comparison of these values as an
internal control since subcellular fractions and whole cells were obtained from different
cell pellets. The difference (∆) between antibiotic accumulation in the subcellular fractions
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and the whole cells is illustrated in figure 2.6 and table 2.2. The difference (∆) was
calculated as ∆ = Mwc – (Mpm + Mcm). Comparatively, the calculated ∆ values were small,
which indicated that the loss of antibiotic during the fractionation process was close to the
minimum. The observed differences may have resulted from experimental errors.

Figure 2.6 The % difference (%∆) between antibiotic accumulation in subcellular fractions
(periplasm and cytoplasm) and whole cells. The % differences were less than 30 for all
fluoroquinolones tested. Ankit Pandeya worked on the accumulation assays for the
compounds with asterisks.
2.3.6

Efflux deficient strain accumulated more fluoroquinolones compared to the
isogenic parent strain

For all fluoroquinolones tested, the accumulated antibiotic in the TolC deficient
strain was higher than the values obtained from the WT strain. This result agreed with our
expectations. However, an unexpected deviation was a higher accumulation in the
periplasm compared to the target site, the cytoplasm. The margin seen in the heterogeneous
accumulation of the antibiotics in the subcellular compartments was more distinct in the
TolC deficient strain.
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2.3.7

Absence of equilibrium between the accumulated antibiotic and the external
concentration.

No active uptake has been reported for fluoroquinolones. The external
concentration of the antibiotics would be expected to equilibrate with the internal
concentration, following free diffusion of the compound. However, results from this study
showed a higher accumulation of the antibiotic in the periplasm compared to the cytoplasm
and whole cell. These values were even higher in the TolC deficient strain than the WT
strain for the fluoroquinolones tested. These results are like findings from other reported
studies190, 191.
2.3.8

Change in cytoplasmic accumulation between an efflux deficient strain and
its parent strain correlated with their MIC ratio.

The effectiveness of an antibiotic against a microbe is reflected by its MIC. It does
not suffice for an antibiotic to accumulate in a cell, the amount that accumulates in the
target region is more relevant. With other factors kept constant, we hypothesize that the
accumulation of an antibiotic in the cytoplasmic region should correlate with its efficacy.
We quantified the subcellular accumulation of nine fluoroquinolones in the TolC deficient
strain and its parent strain. We correlated these values with their respective MIC ratios. We
found a correlation between a change in the cytoplasmic accumulation of these compounds
and the change in their MIC as shown in figure 2.7.
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Figure 2.7 Correlation between MIC and cellular accumulation. Change in MIC between
the wild type and efflux deficient strain plotted against the change in whole cell
accumulation (top) or cytoplasmic accumulation (bottom).
2.4

Discussion
In this study, we investigated the accumulation and distribution of antibiotics in the

subcellular compartments, periplasm, and cytoplasm, of a GN bacterium, E. coli. We
determined the impact of this distribution on the efficacy of the antibiotic. Using a labelfree assay we quantified the concentration of antibiotics that accumulated in a TolC efflux
deficient strain compared to the parent strain. Each of the nine fluoroquinolones had a
higher accumulation in the efflux deficient strain compared to the parent strain. In both
strains, the accumulation of each fluoroquinolone in the periplasm was higher than in the
cytoplasm and the external medium. A previous study by Prochnow et al. showed a higher
accumulation of ciprofloxacin in the periplasm compared to the external medium87. The
DP across the OM of the GN bacteria has been implicated to act as an electrostatic pull on
the fluoroquinolone 61, 91. The presence of the Osmo-regulated periplasmic glucans in the
periplasm may also be an alternative factor that concentrates the charged antibiotic within
that space.
Change in MIC between the wild type and the efflux deficient strains correlated
with the change in cytoplasmic accumulation of these strains and not their whole cell
accumulation. The results obtained in this study agreed with our expectation since the
target for fluoroquinolones, DNA gyrase, is in the cytoplasm. Previous studies have
focused on the whole cell accumulation in GN bacteria 139, 140, 142, 192-194. These studies have
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identified factors that promote penetration and accumulation in GN bacteria to include
relatively small size, higher polarity, presence of amine groups, lower globularity, and
possession of positive charges. These factors hold sway especially when the antibiotics
permeate the cells through porins. Fluoroquinolones chelates Mg2+ and permeate the cells
as net positively complexes. Hence, studying the subcellular accumulation of other families
of antibiotics with distinct characteristics would provide more information on factors that
promote penetration and intracellular accumulation of antibiotics.
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CHAPTER 3. THE OSMOREGULATED PERIPLASMIC GLUCANS AFFECT
SUSCEPTIBILITY OF GRAM-NEGATIVE BACTERIA TO ANTIBIOTICS
3.1

Introduction
The periplasm located between the outer membrane (OM) and inner membrane

(IM) support many specialized functions

57,

including signaling, cell wall rigidity,

enzymatic degradation, protein folding, and biogenesis of the OM, many of which are key
players in the development of drug resistance in GN bacteria 1. Modified complex sugars
known as osmo-regulated periplasmic glucans (OPGs) are highly abundant in the periplasm
195-197.

The structurally linear OPGs are mostly found in E. coli, Shigella flexneri and

Salmonella spp., which are biosynthesized under the control of the opgGH operon198, 199.
The opgH gene encodes a 97 kDa protein, which possesses channel-forming and glucose
residue transferase traits200. The opgG gene encodes a 56 kDa protein that promotes
polymerization during OPGs synthesis58,

200

. OpgB and OpgC have been reported to

contribute to the modification of OPGs through phosphoglycerol addition and
succinylation respectively, which made them to carry negative charges 197, 198, 201-203.
OPGs are important for the interaction between bacteria and external stressors.
Studies have demonstrated that the deletion of opgG and opgH stalled the production of
OPGs while opgB and opgC knockout mutants produced neutral OPG variants202, 204-206.
The sensitivity to antibiotics and host antimicrobial peptides changed with the alteration of
the opgGH operon in GN bacteria

204, 207.

E. coli MC1400 opgB and Shigella flexneri

opgBC mutant strains have been reported to be more sensitive to cellular stress caused by
anionic detergents under low osmotic conditions 202, 208. Due to the net negative charge on
OPGs, we hypothesize that the charge-charge interaction between OPGs and antibiotics
could be a contributor to determine antibiotic susceptibility in GN bacteria. Many
antibiotics are charged or exist as zwitterions 91, 209-212. Depending on the net charge of the
antibiotic, we expect that the OPG-antibiotic interaction could either promote or suppress
the sensitivity to antibiotics in GN bacteria. In this study, we created mutant strains of E.
coli and Salmonella Typhimurium that are defective in OPG biosynthesis to assess the
impact of OPGs on the sensitivity of GN bacteria toward several distinct families of
antibiotics.
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3.2

Materials and methods
3.2.1

Bacterial Strains, Growth Conditions, and Media

The bacterial strains and plasmids used in this study are listed in Table 3.1. The strains
were grown in Luria-Bertani (LB) media at 37ºC with shaking at 250 rpm, except stated
otherwise. The antibiotics used in this study are listed in Table 3.2. All antibiotics were
purchased from Sigma-Aldrich.

Table 3.1 Bacterial strains and plasmids used.
Strain/plasmid

Genotypes or characteristics

Source or reference

E. coli
Choi 213

MG1655

Wild type

MG1655∆opgGH

opgG and opgH deficient strain,
opgGH:kan
opgB and opgC deficient strain,
opgBC:kan
ompC deficient strain; MG1655
ompC:: frt
ompF deficient strain; MG1655
ompF:: frt
ompC and ompF deficient strain;
MG1655 ompF::frt ompC:: frt

MG1655∆opgBC
MG1655∆ompC
MG1655∆ompF
MG1655∆ompCF

This study
This study
Choi213
Choi213
Choi213

S. Typhimurium
SL14028

Wild type

SL14028 ∆opgG

opgG deficient strain;
opgG:kan
opgH deficient strain,
opgH:kan
opgG and opgH deficient strain,
opgGH:kan

This study

pBAD18OpgG

Ampr

This study

pBAD33OpgH

Chlo

r

This study

Chlo

r

This study

SL14028 ∆opgH
SL14028 ∆opgGH

ATCC

This study
This study

Plasmids

pBAD33OpgGH
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Table 3.2 Antibiotics used.
Family

Antibiotics

Net
charge at
physiolog
-ical pH

Behavior in the
cell

Spectrum of
antimicrobial
activity

Aminoglycosides

Amikacin
Gentamicin
Streptomycin
Spectinomycin
Tobramycin

+2 to
+5

Permeate the cell
envelope as largely
positive
antibiotics. Drug
binds to 30s
ribosome in the
cytoplasm and
inhibit protein
synthesis214

Broad spectrum of
activity against both
Gram-positive and
Gram-negative
bacteria especially
the Enterobacter
species215

Oxazolidinones

Linezolid

0

Permeate the cell
envelope in the
uncharged form. It
binds to 23s
ribosome and
inhibits protein
synthesis216

Narrow spectrum of
activity. Uniquely
targeted at antibiotic
resistant Grampositive bacteria
such as methicillin
resistant
Staphylococcus
aureus (MRSA) and
vancomycin resistant
enterococci
(VRE).217, 218

Cephalosporin

Cefuroxime

-1

Permeate the cell
envelope as
negatively charged
antibiotics. It binds
to penicillinbinding proteins in
the periplasm. It
inhibits cell wall
synthesis219, 220.

Broad spectrum
especially against
penicillin susceptible
bacteria strains like
streptococcus
pneumoniae221
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Table 3.2 continued
Fluoroquinolones

Ciprofloxacin
Enrofloxacin
Fleroxacin
Levofloxacin
Marbofloxacin
Ofloxacin

0 to -1

A class of either
zwitterions or
anions that
complexes with
Mg2+ to form
positive
complexes. They
behave as
positively charged
antibiotics when
they permeate the
cell envelope.
They inhibit DNA
gyrase in the
cytoplasm222.

Broad spectrum223

Tetracyclines

Chlortetracycline
Minocycline
Tetracycline

-1

Anions that
complex with
Mg2+ to form
positively charged
species. They
permeate the cell
envelope as cations
and bind to
ribosomes which
leads to the
inhibition of
protein synthesis33.

Broad spectrum224

3.2.2

Construction of Opg Mutant Strains

Gene knockout strains were created using the Quick and Easy E. coli gene deletion
kit (Gene Bridges GmbH, Heidelberg, Germany) following the manufacturer’s protocol.
The target gene on the chromosome was replaced with an FRT-flanked kanamycin
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resistance marker cassette. To construct the double knockout mutant, plasmid pECA102
was introduced to remove the kanamycin cassette as described previously 225.
3.2.3

Extraction of OPGs

The OPGs were extracted as described with some modifications

100, 207, 226.

An

overnight culture of the bacterial cells (3 mL) was sub-cultured into 300 mL lysogenic
broth (LB), with 171 mM NaCl, the cells were grown to OD650 = 1.0 and harvested at 8000
g for 15 min at 4C. Unless stated otherwise, all other operations were performed at room
temperature. The wet weight of the cell pellets was determined. The cells were washed
once in 10 mL PBS (pH 7.4) followed by three successive steps of extraction, first with 20
mL of methanol: chloroform: water (2:1:0.8), then with 31.5 mL chloroform: water (1:0.8),
and finally with an equal volume of ethanol. The ethanol-soluble part was concentrated
through rotatory evaporation to about 2 mL and the concentrated extract was reconstituted
with distilled water to a final volume of 5 mL.
3.2.4

Determination of Sugar Content of OPGs

The amount of sugar present in the OPG extract was determined using the anthronesugar test227, 228. The anthrone reagent stock was prepared by adding 140 mL of distilled
water to 360 mL of concentrated sulfuric acid. 250 mg anthrone and 5 g thiourea were
added to the warm acid mixture and mixed until completely dissolved. The final mixture
was cooled and stored at 4 C. The reagent was ready for use the next day. The reconstituted
extract (500 µL) was diluted 1:1 using distilled water. To the mixture, 5 mL of cold
anthrone reagent was added and the tubes were sealed and shaken vigorously to ensure
complete mixing. The tubes were placed in a boiling water bath for 15 min. Next, they
were cooled in a water bath and absorbance was taken at 620 nm after 20 min. Standards
containing varying concentrations of glucose were also prepared and analyzed
simultaneously.
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3.2.5

Antimicrobial Susceptibility Test and Growth pattern

The MIC values were determined for the antibiotics based on the guidelines
reported by CLSI229. Overnight culture of the bacterial strains was diluted to obtain a final
concentration of 105 CFU/mL in fresh MH Broth (cation adjusted) media (Millipore Sigma,
St. Louis, MO, USA) in a 48 well microtiter plate. A two-fold serial dilution with the
indicated antibiotics was prepared. The plates were incubated at 37 C with shaking at 160
rpm. The cells were incubated with shaking at 160 rpm for 19 hour and the absorbance at
OD600 was measured. The MIC was determined as the lowest concentrations of drug that
inhibit observable cell growth. For growth curves, the absorbance at OD 600 was measured
at times 0 h, 4 h, and then at one-hour intervals until 10 hours. All experiments were
performed in triplicates.
3.2.6

Effect of Ionic Strength on Susceptibility

LB agar dishes with varying concentrations of antibiotics and NaCl were prepared
based on Cold Spring Harbor Protocols230. Overnight culture of MG1655 E. coli cells (1
mL) were inoculated into 100 mL low salt LB (75 mM NaCl) and grown to late log phase.
The cells were harvested and serially diluted in 10-folds from 108 to 104 CFU. Aliquots of
2 L were spotted onto LB-agar dish supplemented with either 300 mM or 600 mM NaCl,
in the presence or absence of varying concentrations of antibiotics. The LB-agar dishes
were incubated overnight (17 hours) at 37C before the photographs were taken.
3.2.7

Membrane Leakage Assay

The integrity of the membrane was determined using the Chlorophenyl red-β-Dgalactopyranoside (CPRG) test as reported by Choi52, 231, 232. Overnight culture of the
bacterial strains (1 mL) was inoculated into 100 mL LB and grown to the stationary phase.
The cells were harvested and diluted to 104 cells/mL. Aliquots of 2 µL were spotted onto
LB-agar dish supplemented with 20 µg/mL CPRG. The LB-agar dish was incubated
overnight (17 hours) at 37 C before its photo was taken.
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3.2.8

Statistical Analysis

We used IBM SPSS version 28.0 for statistical analyses. One-way ANOVA test and
independent samples student t-test were used to ascertain the statistical differences between
the means of test groups, where applicable. A value of p<0.05 was accepted as significant.

3.3

Results
3.3.1

The Effect of OPG on Bacterial Sensitivity to Antimicrobials

To evaluate the effect of OPGs biosynthesis on the sensitivity to antibiotics in GN
bacteria, we created E. coli MG1655 and S. Typhimurium SL14028 mutant strains in which
the opgGH genes were disrupted. Drug susceptibility test was performed to compare the
MIC of opgGH knockout strains with the parent strain. Also, we compared growth
characteristics in cases where the changes were too small to be captured using the MIC
assay. We observed the disruption of OPG synthesis did not lead to increased sensitivity
for any drug tested. For some of them, an approximately 2-8 fold increase in MIC were
observed for the opgGH mutant strain (Table 3.3 and 3.4). The transformation of E. coli
MG1655 opgGH mutant strain with a plasmid expressing the intact opgGH operon restored
the phenotype (Table 3.5). The impact of deleting opgGH was less significant in the S.
Typhimurium SL14028 strains and no MIC change could be observed (Table 3.4).
However, growth curve measurement revealed that in the presence of the positively
charged aminoglycosides, the opgGH mutant strain grew slightly faster compared to the
parent strain (Fig. 3.1). An opposite effect was observed with the negatively charged
cefuroxime. In the presence of uncharged linezolid, there was a slight reduction of growth
although not mathematically significant.
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Table 3.3 Antimicrobial susceptibility test of E. coli MG1655 and its opgGH knock out
strain to distinct families of antibiotics.
Class of drug

Antibiotics

MIC
Wild Type
(WT)

∆opgGH

Fold change

(g/mL)

(∆opgGH/WT)

(g/mL)
Fluoroquinolones

Ciprofloxacin

0.008

0.016

2

Norfloxacin

0.063

0.125

2

Levofloxacin

0.031

0.063

2

Ofloxacin

0.063

0.063

1

Enrofloxacin

0.031

0.031

1

Marbofloxacin

0.031

0.031

1

Fleroxacin

0.063

0.125

2

Gentamicin

0.500

2.000

4

Tobramycin

0.500

2.000

4

Amikacin

0.500

4.000

8

Streptomycin

2.000

16.000

8

Spectinomycin

4.000

16.000

4

Tetracycline

2.000

4.000

2

Chlortetracycline

2.000

4.000

2

Minocycline

2.000

4.000

2

Cephalosporin

Cefuroxime

16.000

16.000

1

Oxazolidinone

Linezolid

256.000

256.000

1

Aminoglycosides

Tetracyclines
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Table 3.4 Antimicrobial susceptibility test of S. Typhimurium SL14028 and its opgGH
knock out strain to distinct families of antibiotics.
Class of drug

Antibiotics

MIC
Wild Type
(WT)

∆opgGH

Fold change

(g/mL)

(∆opgGH/WT)

(g/mL)
Fluoroquinolones

Ciprofloxacin

0.016

0.016

1

Norfloxacin

0.125

0.125

1

Levofloxacin

0.063

0.063

1

Ofloxacin

0.125

0.125

1

Enrofloxacin

0.063

0.063

1

Marbofloxacin

0.031

0.031

1

Fleroxacin

0.125

0.125

1

Gentamicin

0.500

0.500

1

Tobramycin

1.000

1.000

1

Amikacin

2.000

4.000

2

Streptomycin

16.000

16.000

1

Spectinomycin

32.000

64.000

2

Tetracycline

1.000

1.000

1

Chlortetracycline

2.000

2.000

1

Minocycline

1.000

2.000

2

Cephalosporin

Cefuroxime

32.000

32.000

1

Oxazolidinone

Linezolid

256.000

256.000

1

Aminoglycosides

Tetracyclines
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Figure 3.1 Growth curve measurement of S. Typhimurium SL14028 and the opgGH
Knockout strains treated with tobramycin (a), streptomycin (b), Linezolid (c), and
Cefuroxime (d).The growth characteristics of these strains were monitored under three
different conditions (no drug added, highest drug concentration with observable growth
change, and least drug concentration without observable growth change). No MIC changes
were observed for strains treated with these antibiotics (table 3.4). However, growth curve
measurements showed that the disruption of the opgGH operon made the cells grow faster
in the presence of the some positively charged aminoglycosides, which was significant for
streptomycin. The opgGH mutant strain grew significantly slower in response to the
negatively charged cefuroxime. In the presence of uncharged linezolid, there was a slight
reduction of growth although not mathematically significant. Data is an average of three
replicates and reported as mean ± standard deviation. The asterisks indicate a significant
difference with a value of p < 0.05.
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Table 3.5 Antimicrobial susceptibility test of E. coli MG1655, opgGH Knockout, and
∆opgGHpOpgGH strains to distinct family of antibiotics.
Class of drug

Antibiotics

MIC
Wild Type
(WT)

Fold change
(∆opgGH/WT)

Fold change
(∆opgGHpopgGH
/WT)

(g/mL)
Fluoroquinolones

Ciprofloxacin

0.008

2

1

Norfloxacin

0.063

2

1

Levofloxacin

0.031

2

1

Ofloxacin

0.063

1

1

Marbofloxacin

0.031

1

1

Gentamicin

0.500

4

1

Tobramycin

0.500

4

1

Amikacin

0.500

8

2

Streptomycin

2.000

8

1

Tetracycline

2.000

2

1

Chlortetracycline

2.000

2

1

Minocycline

2.000

2

1

Cephalosporin

Cefuroxime

16.000

1

1

Oxazolidinone

Linezolid

256.000

1

1

Aminoglycosides

Tetracyclines
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Figure 3.2 Growth curve measurement of E. coli MG1655, and ∆opgGH strains treated
with cefuroxime (a), and Linezolid (b).The growth characteristics of these strains were
monitored under three different conditions (no drug added, highest drug concentration with
observable growth change, and least drug concentration without observable growth
change). No MIC changes were observed for the strains treated with cefuroxime and
linezolid (table 3.3). However, the disruption of the opgGH operon led to a significantly
slower growth of the bacterial cells in the presence of the negatively charged cefuroxime
and uncharged linezolid. Data is an average of three replicates and reported as mean ±
standard deviation. The asterisks indicate a significant difference with a value of p < 0.05.
3.3.2

The Effect of the Negative Charge of OPGs on the Susceptibility of Bacteria
to Antibiotics
OPGs are negatively charged due to the modifications caused by OpgB and OpgC

in GN bacteria201, 202, 208. In this study, the MIC results showed that the disruption of the
opgGH operon led to a decrease in susceptibility to some of the positively charged
aminoglycosides (Tables 3.3 and 3.4). Some of the fluoroquinolones and tetracyclines,
which are either zwitterions or anions at physiological pH, had a similar behavior as the
positively charged aminoglycosides. This observed similarity in OPG-antibiotic interaction
could be because of the net positively charged complexes formed between Mg2+ and either
fluoroquinolones or tetracyclines. We hypothesize the observed differences in the
sensitivity to the aminoglycosides, fluoroquinolones and tetracyclines could be due to their
interaction with the negatively charged groups on OPGs. Thus, we created E. coli MG1655
mutant strain in which the opgBC gene was disrupted to produce neutral OPGs. A drug
susceptibility test was performed to compare the MIC of the opgBC mutant strain with the
parent strain. In cases where there was no MIC change, we examined for small changes by
monitoring growth. We observed that the disruption of the opgBC gene did not increase
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the sensitivity to any antibiotic tested. The change in MIC observed for the loss of negative
charge in OPGs is like responses seen with the disruption of the opgGH operon. For some
of the antibiotics tested, the treatment of the opgBC mutant strain with the
fluoroquinolones, tetracyclines and the positively charged aminoglycosides, showed an
approximately 2-16 fold increase in MIC compared to the parent strain (Table 3.6). In
addition, the opgBC mutant grew slower in the presence of the negatively charged
cefuroxime and uncharged linezolid (Fig. 3.3).

Table 3.6 Antimicrobial susceptibility test of E. coli MG1655 and opgBC knockout strains
to distinct families of antibiotics.
Class of drug

Antibiotics

MIC
Wild Type
(WT)

∆opgBC

Fold change

(g/mL)

(∆opgBC/WT)

(g/mL)
Fluoroquinolones

Aminoglycosides

Ciprofloxacin

0.008

0.008

1

Norfloxacin

0.063

0.063

1

Levofloxacin

0.031

0.031

1

Ofloxacin

0.063

0.063

1

Enrofloxacin

0.031

0.031

1

Marbofloxacin

0.031

0.031

1

Fleroxacin

0.063

0.063

1

Gentamicin

0.500

2.000

4

Tobramycin

0.500

2.000

4

Amikacin

0.500

8.000

16

Streptomycin

2.000

16.000

8

Spectinomycin

4.000

16.000

4
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Table 3.6 continued
Tetracyclines

Tetracycline

2.000

2.000

1

Chlortetracycline

2.000

4.000

2

Minocycline

2.000

2.000

1

Cephalosporin

Cefuroxime

16.000

16.000

1

Oxazolidinone

Linezolid

256.000

256.000

1

Figure 3.3 Growth curve measurement of E. coli MG1655 and opgBC Knockout strains
treated with cefuroxime (a), and linezolid (b).The growth characteristics of these strains
were monitored under three different conditions (no drug added, highest drug concentration
with observable growth change, and least drug concentration without observable growth
change). The loss of the negative charges on OPGs significantly retarded the growth of the
bacteria cells in response to cefuroxime and linezolid. Data is an average of three replicates
and reported as mean ± standard deviation. The asterisks indicate a significant difference
with a value of p < 0.05.
3.3.3

The Effect of Ionic Strength on the Susceptibility of OPG Mutant Strains to
Antibiotics.
The production of OPGs can be osmotically controlled198, 201. OPGs are maximally

produced under low osmotic conditions and the level of production decreased significantly
when the osmotic pressure increased. Increasing ionic strength could disrupt both the
production of OPGs and the accessibility of the antibiotics into their target compartment in
the cell. To examine the effect of ionic strength on the sensitivity of opg mutant strains to
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antibiotics, we performed a drug susceptibility assay at two different ionic strengths, in the
presence of 300 or 600 mM NaCl. We prepared LB-agar dishes as described in the method
section to examine the impact of ionic changes on the susceptibility of the opg mutant
strains to streptomycin and amikacin. We observed that higher NaCl concentration in the
growth medium led to an increase in resistance to both drugs, suggesting a reduced
accessibility of streptomycin and amikacin into the cytoplasm.
a

b

Figure 3.4 Ionic screening of E. coli MG1655 and opg mutant strains treated with
streptomycin(a), and amikacin (b). LB-agar dishes were supplemented with varying
concentrations of antibiotics and NaCl. Late log phase cells grown in low salt medium (75
mM NaCl) were harvested and diluted from 108 to 104 cells/mL in 10 folds. Aliquots of 2µl
were spotted onto the LB-agar dishes. The cells were incubated overnight (17 hours) at
37C. Increasing the ionic strength of the growth medium from 300 mM to 600 mM NaCl
decreased the accessibility of streptomycin and amikacin into the cytoplasm of the bacterial
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strains. This led to a decrease in the susceptibility of the opg mutant strains to the
antibiotics.

3.3.4

The Effect of OPG Mutation on Membrane Permeability.

OPGs are abundant in the periplasmic space of the cellular envelope of GN bacteria.
It is unclear if changes in the biosynthesis of OPGs would make the cell envelope leaky.
We performed a membrane integrity test by using chlorophenyl red-β-D-galactopyranoside
(CPRG) as a substrate. This test is positive for cells with leaky membranes, as CPRG can
readily penetrate the leaky membrane into the cytoplasm, where it is cleaved by a βgalactosidase (LacZ) to produce cells of a red phenotype52, 232, 233. Alteration of ompC gene
has been shown to disrupt the permeability of the OM of GN bacteria52. Using the ompC
and ompCF mutant strains as positive controls, we performed the CPRG-LacZ test on the
opg mutant strains. We observed that the opg mutant strains and the parent strain had no
red phenotype compared to the positive controls (Fig. 3.5). This indicates that the observed
MIC changes in the opgGH and opgBC mutant strains compared to the parent strain are
not because of a leaky membrane.
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Figure 3.5 LB agar dish supplemented with CPRG showing colonies from E. coli MG1655
cells, wild type (1), ∆ompCF (2), ∆ompC (3), ∆ompF (4), ∆opgGH (5) and ∆opgBC (6).
The mutants with leaky cell envelope accommodate the permeation of CPRG and in the
cell, Lac-Z cleaves CPRG to the product CPR which gives the characteristic red phenotype.
Stationary phase cells grown in LB medium were harvested and diluted to 10 4 cells/ml.
Aliquots of 2µl were spotted onto LB plates. The cells were incubated overnight (17 hours)
at 37C. The ompC and ompCF mutant strains were used as positive controls and ompF
mutant strain served as the negative control. Similar as the negative control, the opg mutant
strains showed no red phenotype.
3.3.5

Knockouts of OpgGH, Not OpgBC, led to a Reduction of the Amount of
OPGs Synthesized Despite an Observation of a Similar Impact on Antibiotic
Susceptibility.

A previous study showed that Shigella flexneri opgBC mutant strain had increased
susceptibility to the anionic detergents SDS and DOC203. This is consistent with the results
we obtained for the negatively charged cefuroxime used in this study (table 3.6). Though
we observed no MIC changes, the opgBC strain grew slower in the presence of cefuroxime.
Another study showed that the disruption of the opgGH operon in S. enterica serovar typhi
SL1344 led to a significant reduction in the amount of OPGs synthesized 234. The disruption
of opgBC is expected not to have an impact on the amount of OPGs synthesized since
OpgB and OpgC play unique roles in the modification of OPGs to carry negative charges.
To evaluate the impact of the opg mutations on the production of OPGs, we extracted the
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total OPGs from the bacterial strains as described in the method section. We used the
anthrone-sugar test to quantify the total hexose sugar content in the OPG extracts. We
compared the sugar content in the opgGH and opgBC mutant strains to the parent strain. It
showed that, compared to the parent strain, the sugar content significantly decreased in the
opgGH mutant strains, but not in the opgBC mutant strain (Fig. 3.6). The transformation
of plasmid expressing the intact opgGH into the E. coli MG1655 opgGH mutant strain
reverted the production of OPGs.

a

b

E. coli MG1655

0.5

Amount (mg/ g wet cell wt. )

0.5

Amount (mg /g wet cell wt)

S. typhi SL14028

0.4
0.3

*
0.2
0.1

*

0.4

0.3

0.2

0.1

0
OPG

Wild type

∆opgGH

∆opgBC

∆opgGHpopgGH

0
OPG
Wild type

∆opgGH

Figure 3.6 Amount of OPGs in E. coli MG1655(a), S. Typhimurium SL14028 (b) and the
opg mutant strains. OPGs were extracted from the strains and the total hexose sugar content
was determined by the anthrone-sugar test. Disruption of the opgGH operon led to a
significant decrease in the sugar contents in both bacterial species. The transformation of
the opgGH mutant strain in E. coli with a plasmid expressing the intact opgGH gene
restored the phenotype. The opgBC mutation did not led to a reduction of sugar content.
Data is an average of three replicates and reported as mean ± standard deviation. The
asterisks indicate a significant difference with a value of p < 0.05.
3.4

Discussion
In this study, we systematically investigated the impact of OPGs and their negative

charge on antibiotic susceptibility in two GN strains, E. coli MG1655 and S. Typhimurium
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SL14028. OPGs are complex sugars of glucose subunits, which are modified at maturation
to contain groups such as succinic acid, phosphoglycerol and phospho-ethanolamine 58, 195,
197.

Previous studies have shown that the total cellular amount of hexose sugar positively

correlated with the amount of OPGs produced in bacterial strains205, 226. Using an anthronesugar test, we assessed the amount of OPGs produced in the opg mutant strains. The
production of OPGs significantly reduced in the opgGH mutant strains in both bacterial
species, when compared to their respective parent strains (figure 3.6). In contrast, the level
of OPGs did not change significantly in the opgBC mutant strain.
The significant reduction in OPG production in the opgGH mutant strains
complemented the decreased susceptibility to antibiotics observed in the MIC result when
compared to the wild type strain (tables 3.3 and 3.4). This suggests that OPGs are important
determinants in the susceptibility of GN bacteria to antibiotics. Literature has shown that
OPGs in GN bacteria are unique because they carry negative charges58. To evaluate the
role of charge in OPG-mediated susceptibility to antibiotics in GN bacteria, we created an
opgBC mutant strain of E. coli that produce neutral OPGs and performed drug
susceptibility test. We hypothesize that the electrostatic interaction between OPGs and
antibiotics in GN bacteria should impact their susceptibility toward drugs differently, based
on the charge state of the compounds. We observed that the opgBC mutant strain had
decreased susceptibility to the positively charged aminoglycosides when compared to the
parent strain (table 3.6). Surprisingly, some of the fluoroquinolones and tetracyclines,
which carry net negative charge, behaved like positively charged aminoglycosides. We
speculate that since these classes of antibiotics are known to form Mg 2+ complexes in the
periplasm, the overall charge state become positive 141, 211, 234-236. The growth curve data
showed that in response to negatively charged cefuroxime, the opgBC mutant strain grew
slower compared to the parent strain (figure 3). These results are similar to the antibioticglucan electrostatic interaction reported in previous studies 211, 212, 236, 237. In summary, ours
and previous studies indicate that negatively charged glucans in the periplasm promote the
intracellular accumulation of positively charged antibiotics which affect the susceptibility
of bacteria to these drugs. This implies that OPGs also contributes to the broadening of the
spectrum of activity for most of these antibiotics with net positive charge tendency. For
instance, antibiotics such as fluoroquinolones and tetracyclines that lack net positive
47

charges at physiological pH, but form net positively charged complexes with Mg 2+, do
possess better antibacterial activity in GN bacteria than linezolid and cefuroxime.
In this study, we also examined the impact of ionic changes on the sensitivity of
opg mutants to antibiotics. Previous studies have shown that the biosynthesis of OPGs is
sensitive to alterations in the ionic strength of the growth media198. High osmotic medium
suppresses OPGs production while low osmotic medium favors the production of OPGs.
This suggests that under varying ionic strength, the sensitivity of the opg mutants to
antibiotics would change. Changing the ionic strength of the growth medium could affect
the sensitivity of the opg mutant strains in two ways. First, alter the production of OPGs.
Second, disrupt the accessibility of the antibiotics into the target region of the cell. To
evaluate the impact of ionic changes on the sensitivity of the opg mutant strains to
antibiotics, we selected streptomycin and amikacin because these two antibiotics showed
the highest MIC changes in the opgBC mutant strain compared to the parent strain (table
3.6). The ionic screening result showed that an increase in the NaCl concentration in the
growth medium by 300 to 600 mM resulted in a decrease in the susceptibility of all strains
to streptomycin and amikacin (Fig. 3.4). The opg mutant strains showed higher resistance
to both antibiotics under the low salt and 300 mM extra salt conditions, this difference
disappeared in the presence of 600 mM extra NaCl. This suggests that the high salt
condition screened off the contribution from electrostatic interaction between OPG and the
cationic antibiotics.
Previous studies have reported the sensitivity of opg mutants of D. dadantii, E. coli
and Shigella flexneri to detergents such as bile acids and SDS147, 202, 208. In a recent study,
Murakami et al. showed that the disruption of the opgGH operon in E. coli led to an
increase in resistance to Cecropin A, an antimicrobial peptide, compared to the parent
strain204. Bhagwat et al. showed that the opgBC mutant strains in Shigella flexneri were
sensitive to sodium deoxycholate203. This type of response to external stressors appears to
be specific to the linear OPGs since they are the common OPG variants in the GN bacteria
S. Typhimurium, Shigella flexneri and E. coli. In addition, these three bacterial species
share other features such as bond types, number of glucose residues, substituents, opgGH
sequence match (approximately 71-94 %), and membership of the OPG family type I58. In
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contrast to linear OPGs, the cyclic variant has been reported to use an alternative
mechanism to alter antibiotic susceptibility in bacteria. For instance, P. aeruginosa cells
produce both cyclic and linear OPGs, and the cyclic OPGs have been reported to protect
bacterial cells by the seclusion of antibiobics238, 239. In this study, we demonstrated that
charge is important to the linear OPGs in mediating antibiotic susceptibility in GN bacteria.
The growth response of the E. coli opgBC mutant strain to cefuroxime is similar to the
increased sensitivity of the opgBC mutant in Shigella flexneri to the anionic detergents
observed by Bhagwat et al203. It is unclear if a similar pattern of response to antibiotics
would be seen for cyclic OPGs possessing succinic acid and phosphoglycerol
modifications in other bacterial species. This would require further investigation.
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CHAPTER 4. THE ROLE OF OSMOREGULATED PERIPLASMIC GLUCANS IN
COPPER TOLERANCE IN GRAM-NEGATIVE BACTERIA

4.1

Introduction
Copper is a trace element essential to biological processes. Copper is essential for

several intracellular processes including the electron transport chain, regulation of
oxidative stress, and melanin synthesis240. Copper plays these essential roles because at
low concentrations copper ion act as a cofactor for many intracellular proteins including
cytochrome c oxidase, superoxide dismutase, and tyrosine240.
Copper ions can also be deleterious to bacteria and other microbes when they are
free and present at high concentrations240-244. One mechanism of copper toxicity is the
generation of reactive oxygen species (ROS) from the redox cycle when copper ions cycle
between Cu+ and Cu2+. Copper ranks top among the inducers of oxidative stress compared
to other heavy metals including zinc, cobalt, cadmium, and iron245. The ROS formed in a
Fenton-like reaction can lead to cell membrane damage by lipid peroxidation, disruption
of the lipopolysaccharides, cell wall damage, protein misfunction, damage of enzymatic
systems, and DNA degradation243, 244, 246-250. Another mechanism of copper toxicity is the
displacement of other essential elements including iron, and zinc from their binding sites.
This displacement leads to deleterious downstream effects in bacteria including the
disruption of the synthesis of branched chain amino acids, citric acid cycle, and pentose
phosphate pathway242.
Components of the OM of GN bacteria that carry negative charges have been
reported as binding targets for copper251. Some of these negative charge-carrying
components are damaged due to copper toxicity while others bind copper to regulate its
intracellular levels. Nan et al. in a previous study showed that E. coli cells exposed to
antibacterial stainless steel (0Cr18Ni9-3.8 wt pct Cu) became leakier than those exposed
to contrast stainless steel (0Cr18Ni9)251. The bacterial response to the antibacterial
stainless steel changed with time, when observed under Atomic Force Microscopy (AFM).
At 3 hours post-exposure, no changes were observed in response to the copper rich steel
compared to the non-copper steel. At 9 hours post-exposure, the OM of the cells exposed
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to the copper rich steel broke down while the inner core of the cell remained intact. At 24
hours, the entire cell collapsed. The observed collapse of the OM at the third hour was
attributed to the binding of Cu2+ to LPS and the disruption of this physical barrier. This
disruptive interaction resulted in the release of the periplasmic content. For instance, the
concentration of K+ in the extracellular medium increased from 1.37 mg/L to 5.76 mg/L 7
hours post-exposure to the antibacterial stainless steel. Exposure to the contrast steel did
not change extracellular concentration of K+ significantly (1.37mg/L to 2.65 mg/L). Hence,
several sectors explore the toxicity of copper as a warfare tool against microbes. In the
health sector, surfaces are coated with copper and copper alloys to reduce the bacterial
burden on them in hospitals252-255. Copper ions are usually released from these metallic
surfaces, when bacteria are in contact with them244, 256 . Farmers have also explored the
toxic potentials of copper on microbes to manage microbial infections on their crops 257.
Bacteria have adapted mechanisms to tolerate copper insult. Some reported
mechanisms include the chelation of copper ions in the extracellular environment, the OM
in GN bacteria acting as an extra protection barrier against copper, copper-scavenging
proteins within the cell, and the copper efflux system

258, 259.

The periplasm of the GN

bacteria houses key players that participate in the homeostasis of copper260-262. These
periplasmic key players include cuproenzymes and chaperones. Bacterial cuproenzymes in
the periplasm include nitrite reductase, nitrous oxide reductase, azurin, laccases, CueO, and
amine oxidases263. The cuproenzymes are compartmentalized within the bacterial cell,
where they bind to free copper, and

regulate its intracellular distribution and

accumulation264. For instance, in E. coli periplasm, CueO converts Cu+ to a less toxic
Cu2+, reducing the entry of toxic Cu+ into the cytoplasm across the IM

265.

Periplasmic

chaperones that contribute to copper homeostasis in bacteria include CusF, PcoA, and
PcoC266, 267. CusF is a component of a well-studied efflux system in E. coli, the resistance
nodulation division (RND)-type CusCFBA system268-270. As a chaperone, CusF provides
excess copper to the CusCFBA efflux system, which has been classified as a very effective
mechanism in curbing copper toxicity. Aside CusF, the other components of the CusCFBA
system include CusC an OM efflux channel, CusB a periplasmic adaptor protein, and CusA
an inner membrane active pump269, 271, 272. Previous studies have shown that the alteration
of the genes that encodes the components of the CusCFBA system and CueO resulted in
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an increased sensitivity to copper immobilized on surfaces244, 273. In bacterial systems
characterized by the absence or inactivation of CueO, PcoA has been reported to be its
functional substitute258, 266, 274. PcoC and PcoE are structured to also bind Cu+ 266, 275.
OPGs are abundant in the periplasm and play an important role in the adaptation of
bacterial cells to osmotic changes58. OPGs are trapped in the periplasm, and they are also
a component of the extracellular polymeric substances (EPS). Previous studies have shown
that OPGs also participate in bacterial response to insult from heavy metals including iron
and zinc276, 277. Javvadi et al. reported the role of OPGs in iron homeostasis in Xanthomanas
campestris and E. coli 278. OPG-deficient strains of these bacterial species lost their ability
to sequester iron under iron-deficient conditions. Under conditions of surplus iron, these
OPG-deficient strains generated free iron-induced ROS. Like copper, free iron produces
ROS, when Fe2+ is oxidized to Fe3+. Xanthomonas campestris possess OPGs in its
periplasm and can also secrete them into the extracellular space as -1,2-glucan279. They
showed that OPGs isolated from Xanthomonas campestris had 20-fold more ironsequestrating ability than other bacterial polysaccharides, which included LPS, mannan,
commercial xanthan, and isolated xanthan. Also, the iron-sequestering ability of
Xanthomonas campestris cyclic -1,2-glucan was at least 2 -fold higher than in other cyclic
glucans in yeast, barley, and euglena. The percentage of ROS positive cells increased from
approximately 5 to 85 in E. coli MG1655 OPG deficient strains (opgG or opgH)
compared to the parent strain, when grown in a low osmotic medium supplemented with
0.5 mM FeSO4. In another study, Guiné et al. used an extended X-ray absorption fine
structure (EXAFS) method to identify the Zn2+ binding sites in three GN bacteria,
Cupriavidus metallidurans, Pseudomonas putida, and E. coli277. The identified Zn2+
binding sites were phosphoester, carboxyl, and sulfhydryl groups. Components of the GN
bacteria cell envelope which includes LPS, peptidoglycan, phospholipid hydrophilic head
groups, proteins and EPS possess modifications that carry the identified binding sites. They
calculated the total site densities for Cupriavidus metallidurans, Pseudomonas putida, and
E. coli to be 56, 16, and 31 Zn per nm2 respectively. These values were larger than the
calculated maximum site densities for LPS (0.14 Zn per nm2), phospholipids (0.4 Zn per
nm2), peptidoglycan (1.8 Zn per nm2). Based on their study since EPS embodies nucleic
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acids, lipids, polysaccharides, and proteins, they suggested that EPS may play a key role
in the binding and retention of Zn2+ among cell envelope components of GN bacteria. The
author believed the binding of Zn2+ to intracellular components other than the cell envelope
components is also relevant. OPGs in the periplasmic space are potential Zn2+ binders since
they possess modifications with carboxyl and phosphoester groups.
The role played by OPGs in copper homeostasis in GN bacteria is still unclear.
Based on the binding interactions between EPS and heavy metals reported in other studies,
we speculate OPGs may be one of the protective mechanisms the GN bacteria adapts
against copper insult276,

277.

OPGs are complex glucans carrying negative charges195 .

Oertiker et al. in a previous study reported higher transcriptional levels of mdoG gene when
the concentration of copper in the extracellular space increased280. The transcriptional
levels of mdoG gene in a GN bacterium, A. ferrooxidans, increased from 0.75 to 1.75
log2(fold change), when copper concentration increased from 100 mM to 300 mM. The
transformation of the A. ferrooxidans mdoG gene into an E. coli strain made it more
resistant to copper insult than the parent strain. Pisani et al. showed in their study that mdoG
transcriptional levels increased in Rhodobacter sphaeroides in response to high
concentration of cobalt but not to Ni and Zn281. To study the role of OPGs on copper
homeostasis in GN bacteria, we performed a green fluorescent protein (GFP)-quenching
assay to examine the tolerance of E. coli MG1655 opg mutants to copper compared to the
parent strain. We also performed a drop test to monitor the growth rate of the E. coli opg
mutants compared to the parent strain. We hypothesize that if OPGs are protective against
high levels of copper, the mutant strains would be more susceptible to copper insult
compared to the parent strain. If the charge on OPGs is important to its protective role
against copper, the opgBC mutant would behave as the opgGH mutant.
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4.2

Materials and Methods
4.2.1

Bacterial Strains, Growth Conditions, and Media

The bacterial strains and plasmids used in this study are listed in Table 4.1. The
strains were grown in Luria-Bertani (LB) media at 37ºC with shaking at 250 rpm, except
stated otherwise. Copper sulphate was purchased from Sigma-Aldrich.

Table 4.1 Bacterial strains and plasmids used in this study.
Strain/plasmid

Genotypes or characteristics

Source or reference

E. coli
Choi 213

MG1655

Wild type

MG1655∆opgGH

opgG and opgH deficient
strain, opgGH:kan
opgB and opgC deficient
strain, opgBC:kan

This study

pBAD18OpgG

Ampr

This study

pBAD33OpgH

Chlo

r

This study

Chlo

r

This study

r

Addgene282

MG1655∆opgBC

This study

Plasmids

pBAD33OpgGH
pCK301

Amp

4.2.2

Drop Test Assay

LB agar dishes with varying concentrations of CuSO4 were prepared with some
modifications as described previously

283.

Overnight culture of MG1655 E. coli cells (1

mL) and the opg mutant strains were inoculated into 100 mL LB and grown to late log
phase. The cells were harvested and serially diluted in 10-folds from 108 to 104 CFU. Drops
of 2 L were spotted onto LB-agar dish supplemented with 1.0 mM, 1.5 mM, 2.0 mM, and
2.5 mM of CuSO4. The LB-agar dishes were incubated overnight (17 hours) at 37C before
the photographs were taken.
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4.2.3

GFP-Quenching Assay

GFP-Quenching assay was performed as described previously271, 284-286. Overnight
culture of the bacterial strains transformed with pCK301 was diluted 1:100 into 30 mL
fresh LB and incubated with shaking at 250 rpm for 3 hr at 37C. The plasmid pCK301
possess the insert PrhaBAD-sfGFP. Rhamnose was added to the culture to a final
concentration of 1 mg/mL to induce the expression of GFP for 4h. The cells were spun at
3000 g for 10 min, and the harvested cells were resuspended in 10 mL 20 mM Tris buffer
(pH 7.0). The absorbance at OD660 was measured. The cells were again spun at 3000 g, and
the cells were adjusted to OD660=1.0 by resuspending in 20 mM Tris buffer (pH 7.0). For
the measurement of fluorescence intensity, to 1 mL of 4 mM CuSO 4, 1 mL of the
OD660=1.0 cells were added at approximately 20s following the start of the reading.
Fluorescence measurements were done using a PerkinElmer precisely LS-55 fluorescence
spectrofluorometer and set at intervals of 2 s for 400s. In this study, the excitation and
emission wavelengths were set at 440 nm (slit 15 nm) and 500 nm (slit 5 nm) respectively.
Previous studies have used the following excitation/emission wavelength pairs 395 nm
/509 nm284 and 440 nm /500 nm271.

4.3

Results

4.3.1

The Effect of OPG Mutation on Bacterial Sensitivity to Copper Toxicity

A previous study by Oertiker et al. showed an increase in the levels of mdoG genes
in Acidithiobacillus ferrooxidans in response to increasing concentration of Cu2+ 280. Other
studies have reported the binding of heavy metals such as Zn and Fe to OPGs and EPS 277,
278.

At high concentrations, free copper like other heavy metals generate ROS that are toxic

to bacteria. Several cell envelope components in GN bacteria including chaperones,
cuproenzymes, and polysaccharides interact with copper to regulate its intracellular levels.
We performed a drop-test assay to examine the impact of the disruption of the opgGH
operon on the sensitivity of E. coli to Cu2+. We observed no change in the sensitivity of
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the opg mutants to copper insult with an increase in copper concentration from 1.0 mM to
2.5 mM compared to the parent strain.

Figure 4.1 Drop-test assay showed that the disruption of opgGH operon and opgBC gene
in E. coli resulted in no change in sensitivity to Cu2+ compared to the parent strain. LBagar dishes were supplemented with varying concentrations of CuSO4. Late log phase cells
grown in LB were harvested and diluted from 108 to 104 cells/mL in 10 folds. Aliquots of
2µl were spotted onto the LB-agar dishes. E. coli MG1655 (1), opgGH (2), opgBC (3) and
opgGHpOpgGH (4) are shown on the upper panel. E. coli MG1655-pCk301 (a), opgGHpCk301 (b), and opgBC-pCK301 (c) are shown on the lower panel. The cells were
incubated overnight (17 hours) at 37C. Increasing the ionic strength of the growth medium
from 1.5 mM to 2.5 mM CuSO4 resulted in no change of the sensitivity of the opg mutant
strains to Cu2+ compared to the parent strain.
4.3.2

The Effect of OPG Mutation on Copper Cytosolic Accumulation

To evaluate the effect of OPG mutation on the cytosolic accumulation of copper in
GN bacteria, we transformed pCK301 into E. coli MG1655 and the opg mutants. The
pCK301 carrying the PrhaBAD-sfGFP insert can be induced by rhamnose to fluoresce
green. We observed the disruption of OPG synthesis led to a faster drop in the fluorescence
of GFP in the opgGH mutant compared to the parent strain when copper concentration
increased (figure 4.2). A delay in the quenching effect of copper on GFP was observed
when the ionic strength of the external medium was increased from 0 mM to 250 mM.
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b

c
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d

Figure 4.2 Effect of opgGH operon disruption on copper entry into the cytoplasm of E. coli
MG1655 and the opg mutant strains. The effect of increasing the concentration of copper
on the bacterial strains was determined by the extent of fluorescence quenching in cells
transformed with pCK301. Disruption of the opgGH operon and loss of the negative
charges on OPGs led to a faster drop in GFP fluorescence intensity compared to the wild
type. Increasing the ionic strength of the external medium from 0 mM to 250 mm resulted
in a delay in the quenching effect of copper on GFP.
4.4

Discussion

In this study, we investigated the impact of OPGs and their negative charges on the
sensitivity of a GN bacteria strain, E. coli MG1655 to copper penetration and accumulation.
OPGs are complex sugars of glucose subunits, which are modified at maturation to contain
groups such as succinic acid, phosphoglycerol and phosphoethanolamine 195-197. A previous
study has shown increased transcriptional levels of mdoG in a GN bacteria strain, A.
ferrooxidans280. They proposed OPGs may contribute to the protection of the bacterial
strain against copper insult. Other studies have shown the protective role of OPGs and EPS
in GN bacteria against other heavy metals including zinc and iron 276-278. High
concentrations of free heavy metals in the cell generate ROS, which can cause downstream
damages to the cell243, 245, 246. The special glucans carrying negative charges bind to heavy
metal cations and retain them in the periplasm or extracellular space. This results in a
reduction in the production of ROS and lowers the toxicity of these metal cations in the
bacterial cells. We speculate that the same mechanism would be adapted by GN bacteria
in handling copper toxicity.
58

First, we performed a drop-test assay to examine the sensitivity of the opg mutants
to copper penetration and cellular accumulation. The results showed no change in
sensitivity to copper in the opg mutants compared to the parent strain, when Cu2+
concentration in the external medium increased from 1.5 mM to 2.5 mM. We expected
OPGs to concentrate Cu2+ in the periplasm, make more of the ions available to the
cytoplasm, as observed with the positively charged antibiotics used in our previous study
(chapter three). No change in sensitivity was observed using the drop assay. Tree et al.
showed in a previous study that a cueO mutant of E. coli MC4100 grown aerobically in a
Chemlex-treated M9 minimal medium (M9C) had an elevated sensitivity to increasing
concentration of copper from 0 M to 10 M when compared to the parent strain287. At the
high copper concentration, no growth was observed for the cueO mutant strain. The impact
of copper toxicity of the cueO mutant strain was screened out when the growth medium
was supplemented with varying concentrations of zinc, manganese, or ferrous iron. The
growth of the cueO mutant strain was restored at low concentrations of 250 M (Zn2+), 50
M (Mn2+), and 600 M (Fe2+) respectively. Their result also showed that 100 M
superoxide quencher 1,2-dihydroxybenzene-3,5-disulfonic acid and not the hydroxyl free
radical quencher mannitol suppressed the toxic impact of 10 M copper ion on the cueO
mutant strain, which is an indication that copper toxicity is mediated by the release of
superoxide anions into the cytoplasm. Although an equilibrium of the two chemical forms
of copper is prevalent in the cell, Cu2+ is dominant in the periplasm (an oxidizing
compartment) and the Cu+ is abundant in the cytoplasm (a reducing compartment)270, 288,
289.

We speculate the production of the less toxic Cu2+ was maintained by CueO in both the

opg mutant strains and parent strain used in this study since cueO mutant strains were not
used. Even though OPGs were absent in the E. coli opg mutant strains, the less toxic Cu2+
maintained by CueO had no observable impact on the sensitivity of the opg mutant strains
compared to the parent strain.
Second, we used a GFP-quenching test by copper to examine the rate of entry of
copper into the cytoplasm of E. coli strain opgGH and opgBC. The GFP-quenching test
is rapid and very sensitive. Our results showed a faster drop and lower steady state of GFP
fluorescence in the opg mutant strains compared to the parent strain. After adding the Cu2+
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solution, GFP attained its maximum fluorescence at approximately the 28s time point for
all strains before the onset of quenching. The maximum fluorescence intensity dropped
until a steady state was attained at approximately the 100s time point. At this point, the
fluorescence intensity dropped to levels 1.56, 1.70, and 1.73 folds less than the maximum
fluorescence for the wild type, opgGH and opgBC respectively (figure 4.2 a). The
alteration of the ionic strength of the medium did not change the time at which the
maximum fluorescence was attained for all strains. However, the time points to attain the
steady state shifted to approximately 150, 260, and above 400s when the ionic strength
changed to 10, 50, 250 mM NaCl respectively (figure 4.2 b, c, d). At the ionic strength of
10 mM NaCl, the maximum fluorescence dropped to levels 1.59, 1.75, and 1.68 folds less
than its initial value to attain the steady state for the wild type, opgGH and opgBC
respectively (figure 4.2 b). At 50 mM NaCl, these values were 1.25, 1.64, and 1.51 folds
respectively.
A faster drop of fluorescence indicates that the copper ions entered the cytoplasm
at a faster rate, which is consistent with the lack of OPGs or negative charges on the OPGs
in the periplasm. The absence of OPGs in the periplasm could slow down the penetration
of positively charged copper ions on their entrance into the cytoplasm, at least for the initial
state before it reaches saturation. The lower steady state fluorescence, or higher cytosolic
accumulation of copper ions, in the mutant strains is opposed to our expectation that the
charge-charge interaction between OPGs and cations in the periplasm would lead to
eventual higher accumulation in the cytoplasm as observed for the positively charged
antimicrobials (chapter three). In the presence of OPGs (parent strain), we expected more
Cu2+ ions to be made available to the cytoplasm, to establish an equilibrium between the
two subcellular compartments. The observed behavior could be due to certain reasons.
First, the mechanism of OPGs’ retention of heavy metals in the periplasm may be different
from that of the positively charged antimicrobials. Second, the GFP-quenching assay was
only for 400 s, which may be too short for the ionic distribution. However, increasing the
ionic strength of the external medium resulted in a delay in the quenching of GFP by copper
in both the opg mutant strains and the parent strain. Previous studies have shown elevated
levels of outer membrane porin (OmpC) and outer membrane protein ComC in E. coli
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under high copper concentrations290, 291. The route of copper permeation across the OM is
still unclear but OmpC has been proposed to contribute to copper resistance in GN bacteria
by selectively excluding copper during cation flux into the cell288,

290, 291.

These OM

proteins may contribute to the defensive role of the GN bacteria cell envelope against
copper insult. Other studies have shown the increased expression and permeability of
OmpC under conditions of increasing ionic strength103. The reduction in the entry of copper
ions into the cytoplasm of the E. coli strains evidenced by the delay in the fluorescence
quenching of GFP may be attributed to the elevated expression of OmpC with the
increasing ionic strength of the external medium. However, 400s of the GFP-quenching
assay is too short to allow for an increased expression of OmpC in the bacterial strains.
Hence, the increased entry of copper into the cytoplasm in the opg strains compared to the
parent strain, is most likely due to the absence of OPGs in the periplasm. Also, the
increased ionic strength of the external medium from 10 mM to 250 mM NaCl may have
generated a pool of cations that competed with Cu2+ for entry into the cytoplasm of both
the parent strain and the opg mutant strains. This suggested that charge and ionic strength
play an important role in the cellular accumulation of copper ions.
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CHAPTER 5. DISCUSSION AND FUTURE DIRECTION

Multidrug resistance in bacteria is associated with rising cases of bacterial
infections and it is a big concern around the globe. The gap in the discovery of novel
antimicrobials has made arduous the war against multidrug resistance in bacteria. The
presence of the OM in GN bacteria has created a stiffer barrier to the penetration and the
antibacterial activity of most known antibiotics. The projects in this thesis focused on
understanding the permeability of antibiotics across the cell envelope of GN bacteria. We
first examined the distribution of fluoroquinolones in the two aqueous compartments of E.
coli. Next, we investigated the impact of osmo-regulated periplasmic glucans on the
susceptibility of two GN bacteria to antibiotics. Last, we assessed the role of osmoregulated periplasmic glucans on copper homeostasis in E. coli.
The focus in other studies has been on the whole cell accumulation of antibiotics
and trace elements, and how it depends on factors that influence penetration of antibiotics
across the cell envelope of GN bacteria. We shifted our focus to subcellular accumulation
of antibiotics in GN bacteria. We speculated that the accumulation in the target region of
the cell would be a more important determinant of the efficacy of an antibiotic. We
examined the distribution of nine fluoroquinolones in the subcellular compartments of E.
coli BW25113 and the efflux deficient strain (tolC). We determined the correlation
between the change in MIC of each fluoroquinolone and its accumulation in the bacterial
strains. We observed a higher cellular accumulation of each fluoroquinolone in the tolC
compared to the parent strain. Each fluoroquinolone was heterogeneously distributed
between the subcellular compartments, with a higher accumulation in the periplasm than
in the cytoplasm and the external medium. A correlation was found between the change in
cytoplasmic MIC and the change in compound accumulation in that region. As speculated,
no correlation was found between change in MIC and change in whole cell accumulation.
More insights would be gained from the investigation of the distribution of other classes
of antibiotics in the periplasm and cytoplasm of GN bacteria. In this study, we took
advantage of the intrinsic fluorescence of fluoroquinolones to develop a label-free
accumulation assay. However, quantifying the subcellular accumulation of most other
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classes of antibiotics would require more sophisticated techniques such as mass
spectroscopy.
The observation that fluoroquinolones accumulated higher in the periplasm than in
the cytoplasm established the basis for the second project. Based on previous studies and
ours, we speculated that some chelators or electrostatic interactors may exist in the
periplasm that acts to concentrate the fluoroquinolones within that space. Fluoroquinolones
can form positively charged complexes with Mg2+. Also, negatively charged OPGs are
trapped within the periplasm where they contribute to the development of a negative DP
across the OM. We speculated that the OPGs would be possible electrostatic interactors
with charged antibiotics, which could influence their accumulation within the periplasm
and their efficacy. Hence, we investigated the impact of osmo-regulated periplasmic
glucans on the susceptibility of GN bacteria to antibiotics. We focused on the impact of the
negative charges on the OPGs. We created E. coli and S. typhimurium strains deficient in
OPG production (opgGH) and an E. coli strain devoid of the negative charges (opgBC).
The opgGH bacterial strains were less susceptible to some of the positively charged
aminoglycosides. Some of the fluoroquinolones and tetracyclines, which can form
positively charged complexes behaved in like fashion as the aminoglycosides. In contrast,
the opgGH strains grew slower in the presence of negatively charged cefuroxime and
neutral linezolid. A similar pattern of response to these distinct families of antibiotics was
observed with the opgBC strain. The GN bacteria used in this study belong to the OPG
family I, which are characterized by the presence of linear OPGs. While the responses in
this study appear to be common with the linear variants of OPGs, a future study would be
necessary to investigate the impact of succinic acid and phosphoglycerol modifications of
cyclic OPGs on the susceptibility of bacteria to antibiotics.
The third project was conceptualized based on the interaction that exist between
OPGs and charged antibiotics. We speculated that since OPGs are negatively charged, they
could act as electrostatic interactors to influence the subcellular distribution of Cu2+ in E.
coli and its toxicity in the cell. We performed a drop-test assay, and the result showed no
change in the sensitivity of the opg mutant strains to Cu2+ ions when its concentration in
the LB-agar dishes was increased. We also performed a GFP-quenching assay. We
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transformed pCK301 into E. coli MG1655 and the opg mutant strains, to make them
express GFP. We speculated that both the opgGH and opgBC strains would lack the
ability to concentrate Cu2+ ions, less of the ions would be made available to the cytoplasm,
and the Cu2+ quenching effect on GFP would be less in these opg mutant strains compared
to the parent strain. Our results opposed the initial hypothesis. We observed a quicker
quenching of GFP by Cu2+ in the opg mutants compared to the parent strain, and higher
concentration of Cu2+ in the cytoplasm at the steady state. We speculate the differences in
the rate of fluorescence quenching between the opg mutants and the parent strain could be
due to the absence of the OPGs to delay the initial copper ions penetration within the
periplasm. The extent of contribution of OPGs to copper homeostasis compared to the
CusCFBA efflux system remains unclear. A future study will require the creation of a
double mutant strain with alteration in the opgGH operon and the CusF chaperone. The
roles of CusF and the CusCBA efflux system in copper are relatively established. Hence,
a opgGHcusF and opgBCcusF would give more insights into the role of OPGs in
copper homeostasis. Similarly, with the elevated sensitivity of cueO E. coli mutant strain
to copper toxicity observed in previous studies, the creation of opgGHcueO and
opgBCcueO will also add to the understanding of copper homeostasis in GN bacteria.
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